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1.  INTRODUCTION
1.1. Immediate release (IR) dosage forms
Immediate release dosage forms are conventional dosage forms that allow the
drug  to  dissolve  in  the  gastrointestinal  tract  with  no  intention  of  delaying  or
prolonging the drug dissolution or  absorption.  Specifications  regarding dissolution
characteristics of immediate release dosage forms indicate that at least 85% of the
drug should be dissolved in a 60 minutes ( Karim Amigh et al., 2006).
Some Limitations of Immediate Release Dosage forms
 In conventional oral dosage forms, there is little or no control over the release
of the drug and effective concentration at the target site can be achieved by
intermittent administration of glossy excessive doses.
 The  dosing  pattern  in  conventional  dosage  forms  results  in  constantly
changing,  unpredictable  and  often  sub-therapeutic  plasma  concentrations,
leading to marked side effects in some cases. 
 The rate and extent of absorption of drug from conventional formulations may
vary greatly, depending on the factors such as physicochemical properties of
the  drug,  presence  of  excipients,  various  physiological  factors  such  as  the
presence or absence of food, pH of the Gastrointestinal tract, Gastrointestinal
motility and so on. 
 Poor patient compliance, increased chances of missing the dose of a drug with
short half-life for which frequent administration is necessary. 
 The  unavoidable  fluctuations  of  drug  concentration  may  lead  to  under
medication or over medication. 
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 A typical  peak-valley  plasma  concentration-time  profile  is  obtained  which
makes attainment of steady-state condition difficult (Chein, Y. W. 1992).
 The fluctuations in drug levels may lead to precipitation of adverse effects
especially  of  a  drug  with  small  Therapeutic  Index  (TI)  whenever  over
medication occur. 
 1.2. Sustained Release Dosage Forms
Sustained release technologies can improve the therapeutic efficacy and safety
of a drug by precise temporal and spatial placement in the body, thereby reducing
both the size and number of doses required. Furthermore, the possibility of repeating
successful drugs, coupled with the increasing expense in bringing new drug entities to
market, has been instrumental in generating interest in sustained-release dosage forms
(R.K.Khar & S.P.Vyas, 2002).
The aim of  oral  sustained  release  dosage  forms  is  to  achieve  a  prolonged
therapeutic effect by continuously releasing medicament over an extended period of
time after administration of a single dose. Sustained release constitutes any dosage
form that provides medication over an extended time period. In general, the Sustained
release  dosage  form is to maintain therapeutic  blood or tissue level  of  drug for a
prolonged  period  usually  accomplished  by attempting  slow first  order  fashion.  In
recent years sustained release dosage forms continuous to draw attention in the field
of research for improved patient compliance and decreased incidence of adverse drug
reaction (Rubinstein, M. H, 2000).
The sustained release dosage form is defined as “any drug or dosage form
modification that prolongs the therapeutic activity of the drug”. Once the maximum
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level is reached, the amount of drug in the body decrease slowly, so it will take longer
to drop below the therapeutic range. 
The  terms  sustain  or  controlled  drug  release  incorporates  the  element  of
prolongation  of  duration  of  drug  action  as  well  as  the  drug  predictability  and
reproducibility in drug release kinetics. Polymeric sustained drug delivery systems
offer  numerous  advantages  when  compared  with  conventional  dosage  forms,
including  improved  efficacy,  reduced  toxicity,  and  improved  patient  compliance
(Grass, G. M. & Robinson, J. R, 1990).
Figure 1: Typical plasma drug concentration – profiles for conventional tablet or
capsule  formulation,  a  sustained  release  and  an  oral  controlled  release
formulation (Kewal K & Jain MD, 2008).
Potential Advantages of Sustained Release Dosage Forms 
 Improved patient compliance (Grass, GM, 1990)
 Less frequent dosing (by reducing number of doses). 
 Reduced patient care time.
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 Decreased local and systemic side effects. 
 Reduced Gastrointestinal irritation and other dose related side effects.
 Improved efficiency in the treatment.
 Optimized therapy (Japanese Pharmacopoeia).
 More uniform blood concentration. 
 Reduction in fluctuation in drug level  and hence uniform pharmacological.
response (Robinson, R & Lee, V. H, 1995).
 Cure or control of condition more promptly. 
 Reduction in the incidence and severity of  untoward  systemic  side effects.
related to high peak plasma drug concentrations.
 Maintenance  of  the  therapeutic  action  of  a  drug during  overnight  no  dose
period (Lordi, N et. al, 1991).
 e.g.: Overnight management of pain in terminally ill patient’s permits
improved sleep.
 Employ less total drug.
 Minimum drug accumulation on chronic dosing 
 Economy (Lee, V. H. L et al., 2001).
Disadvantages of Sustained release dosage forms
 They are costly.
 Dose dumping. 
 Increased variability among dosage units. 
1.3. Matrix devices 
Matrix devices consist of drug dispersed homogenously throughout a polymer
matrix.  In  the model,  drug in the outside layer  exposed to the bathing solution is
dissolved first and then diffuses out of the matrix (Remington, 2000).
This process continues with the interface between the bathing solution and the
solid drug moving toward the interior.  For  this system, rate of dissolution of drug
particles within the matrix must be much faster than the diffusion rate of the dissolved
drug leaving the matrix.
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Derivation of  the mathematical  model  to  describe  this  system involves the
following assumptions:
 A pseudo steady state is maintained during drug release. 
 The bathing solution provides sink conditions at all times
 The diameter of the drug particles is less than the average distance of drug
diffusion through the matrix. 
 The  diffusion  coefficient  of  drug  in  the  matrix  remains  constant  i.e.  no
change occurs in the characteristics of the polymer matrix. 
 The rate of release of drugs dispersed in an inert matrix system, have been
derived by Higuchi’s         
dM = Codh-(Cs/2)dh ………….... (1)
Where,
dM = Change in the amount of drug released per unit area.
dh = Change in the thickness of the zone of matrix that has been depleted of
drug.
C0 = Total amount of drug in a unit volume of the matrix.
Cs = Saturated concentration of the drug within the matrix.
From diffusion theory,
dM = (DmCs/h).dt ……………. (2)
Where
Dm = diffusion coefficient in the matrix.
Equation (1) and (2) integrating and solving for 'h' gives,
M= [CsDm (2Co-Cs) t] 1/2……… (3)
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When amount of drug is in excess of the saturation concentration, that is C0>>Cs,
M= [2 Cs Dm C0t] 1/2………… (4)
Equation (4) indicates that the amount of drug released is a function of the square root
of time-
The drug release from a porous or granular matrix can be described by
M= (Ds.Ca.{P/T}.[2C0-PCa]t)1/2
            Where
P = Porosity of the matrix.
T = Tortuosity.
Ca= Solubility of the drug in the release medium.
Ds= Diffusion coefficient in the release medium.
The system is slightly different from the previous matrix system in that the
drug is able to pass out of the matrix through fluid filled channels and does not pass
through the polymer directly.
 Advantages of matrix diffusion system
 Easier to produce than reservoir devices.
 Can deliver high molecular weight compounds.
 Disadvantages of matrix diffusion system
 Can not obtain zero order release.
 Removal of remaining matrix is necessary for implanted systems.
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Figure 2:  Mechanism of drug release from the matrix tablet.
Physicochemical properties 
Aqueous solubility and pKa
A drug to be absorbed it first must dissolve in the aqueous phase surrounding
the  site  of  administration  and  then  partition  into  the  absorbing  membrane.  The
physicochemical  properties  of  a  drug  that  influence  the  absorption  are aqueous
solubility  and  pKa. These properties play an influential role in the performance of
controlled release systems (Remington, 2000)
.
The aqueous solubility of a drug influences its dissolution rate, which in turn
establishes  its  concentration  in  solution  and  hence  the  driving  force  for  diffusion
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across membrane. Dissolution rate is related to aqueous solubility as shown by the
Noyes-Whitney equation that under sink condition is:
Dc/dt=KDACs
               Where,
Dc/dt = Dissolution rate
KD   = Dissolution rate constant
A      = Total surface area of the drug particles.
Cs      = Aqueous saturation solubility of the drug.
The dissolution rate is constant only if surface areas ‘A’ remain constant, but,
as the initial rate is directly proportional to aqueous solubility (Cs), it can be used as a
first approximation of its dissolution rate. Drugs with low aqueous solubility have low
dissolution rates and usually suffer oral bioavailability problems.
Aqueous solubility of weak acids and bases is governed by the pKa of the
compound and pH of the medium.
For weak acids,
St = S0 (1+Ka/ [H+]) = S0 (1+10 pH-pKa)…………. (1)
                   Where,
St = Total solubility (both ionized and un-ionized forms) of the weak acid
S0 = Solubility of the un-ionized form
Ka= Acid dissociation constant
H+= Hydrogen ion concentration of the medium
Equation (1) predicts that the total solubility, ‘St’ of a weak acid with a given
pKa can be affected by the pH of the medium.
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For a weak base,
St = S0 (1+ [H+]/Ka) = S0 (1+10pKa-pH)……… (2)
          Where,
St = Total solubility (both conjugate acid and free base forms) of the weak
base.
S0 = Solubility of the free base form.
Ka = Acid dissociation constant of the conjugate acid
So total solubility (St), of a weak base with a given pKa can be affected by the
pH of the medium.
Extremes in the aqueous solubility of a drug are undesirable for formulation
into controlled release product. A drug with very low solubility and a slow dissolution
rate will exhibit dissolution-limited absorption and yield an inherently sustained blood
level. Formulation of such a drug into a controlled-release system may not provide
considerable benefits over conventional dosage forms. 
Any system relying upon diffusion of drug through a polymer as the rate-
limiting  step  in  release  would  be  unsuitable  for  a  poorly  soluble  drug,  since  the
driving force for diffusion is the concentration of drug in the polymer or solution, and
this concentration would be low. For a drug with very high solubility and a rapid
dissolution rate, it often is quite difficult to decrease its dissolution rate and slow its
absorption. Preparing a slightly soluble form of a drug with normally high solubility
is, however, one possible method for preparing controlled release dosage forms.
Partition coefficient
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A  drug  to  show  its  action  must  diffuse  through  a  variety  of  biological
membranes  that  act  primarily  as  lipid  like  barriers.  Apparent  Oil/Water  Partition
Coefficient (K) explains the penetration of drug through the lipid membranes and can
be defined as, 
K=C0/Cw
Where,
C0 =  Equilibrium concentration  of  all  forms  of  the  drug  e.g.,  ionized and
unionized in an organic phase at equilibrium. 
Cw = Equilibrium concentration of all forms in aqueous phase.
Drugs  with  large  values  of  'K'  are  very  oil  soluble  and will  partition into
membrane readily. According to Hansch correlation, the logarithm of the activity of a
drug or its ability to be absorbed and the logarithm of its partition coefficient having
parabolic relationship.
The explanation for this relationship is that the activity of a drug is a function
of its ability to cross membranes and interact with the receptor. The more effectively a
drug crosses membranes, the greater its activity. 
The Partition Coefficient value should be optimum for effective permeation
and  better  activity.  The  value  of  K  at  which  optimum  activity  is  observed  is
approximately  1000/1.  Drugs  with  K  value,  which  is  higher  or  lower  than  the
optimum, are poorer candidates for formulation into controlled-release dosage forms.
Drug stability
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One important factor for oral dosage forms is the loss of drug through acid
hydrolysis and/or metabolism in the GI tract. Since a drug in the solid state undergoes
degradation at a much slower rate than a drug in suspension or solution, it is possible
to improve the relative bioavailability of a drug that is unstable in GI tract by placing
it in a slowly available controlled release form. For those drugs that are unstable in the
stomach, the most appropriate controlling unit would be one that releases its content
only in  the  intestine.  For  those  drugs  that  are  unstable in  the environment  of  the
intestine, the most appropriate controlling unit in this case would be one that releases
its contents in the vascular space for controlled drug release to extravascular tissues,
but  only for  those  drugs  that  exhibit  a  high  degree  of  binding.  Thus,  the  protein
binding nature of a drug plays significant role in its duration of therapeutic effect.
Extensive  binding  to  plasma  proteins  will  be  evidenced  by  a  long  half-life  of
elimination for the drug and such drugs generally do not require a controlled–release
dosage form. Drugs some times may bind to biopolymers in the GI tract, which could
have an influence on controlled-drug delivery.
Molecular size and diffusivity
Drugs  in  many  controlled-release  systems  must  diffuse  through  a  rate
controlling membrane or matrix. The ability of a drug to diffuse through membranes,
it is so called diffusivity, (diffusion coefficient), is a function of its molecular size (or
molecular  weight).  It  is  possible  to  relate  log  D empirically  to  some function  of
molecular size as.
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Log D = - Sv log V + Kv = - Sm logM + Km
                  Where, 
V = molecular volume.
M = molecular weight.
Sv, Sm, Kv, Km = constant.
The value of 'D' thus is related to the size and shape of the cavities as well as
size and shape of drugs. ‘D’ value for drugs with intermediate molecular weight (150
to 400), through flexible polymers range from 10-6 to 10-9 cm2/sec, with values on the
order of 10-8 being most common.
 For drugs with molecular weight greater than 500, the ‘D’ value in many
polymers frequently are so small that they are difficult to quantify, i.e., less than 10-12
cm2/sec.  Thus,  high  molecular  weight  drugs  and  or  polymeric  drugs  should  be
expected  to  display very  slow release  kinetics  in  controlled-release  devices  using
diffusion through polymeric membranes or matrices as the releasing mechanism.
 Biological properties
Absorption
The rate, extent and uniformity of absorption of a drug are important factors
when considering formulating into a controlled-release system. Since the rate-limiting
step in drug delivery from a controlled-release system is its release from a dosage
form, rather than absorption, a rapid rate of absorption of drug relative to its release is
essential if the system is to be successful. This becomes most critical in the case of
oral administration. Assuming that the transit time of a drug through the absorption
area of the GI tract is between 9 and 12 hrs, the maximum absorption half-life should
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be 3 to 4 hrs. This corresponds to a minimum absorption rate constant Ka of 0.17 to
0.23 hr-1 necessary for about 80 to 95 % absorption over a 9 to 12 hrs transit time.
For a drug with a very rapid rate of absorption (i.e. Ka >> 0.23 hr-1), the above
discussion implies that a first order release rate constant Kr < 0.17 hr-1 is likely to
result  in  unacceptably  poor  bioavailability  in  many  patients.  Therefore,  slowly
absorbed drugs will be difficult to formulate into controlled release systems where the
criterion that Kr <<< Ka must be met.
Distribution
The distribution of a drug into vascular and extra vascular spaces in the body
is an important factor in its overall elimination kinetics. Two parameters that are used
to  describe  the  distribution  characteristics  of  a  drug  are  its  Apparent  Volume  of
Distribution and the ratio of drug concentration in the tissue to that in plasma at the
steady  state,  the  so  called  T/P  ratio.  The  magnitude  of  the  Apparent  Volume of
Distribution can be used as a guide for additional studies and as a predictor for a drug-
dosing regimen and hence the need to employ a controlled release system.
Metabolism
Drugs that are significantly metabolized before absorption, either in the lumen
or tissue of the intestine, can show decreased bioavailability from slower releasing
dosage  forms.  Most  intestinal  wall  enzyme systems  are  saturable.  As the  drug  is
released at a slower rate to these regions, less total drug is presented to the enzymatic
process during a specific period allowing more complete conversion of drug to its
metabolite. Formulation of these enzymatically susceptible compounds as prodrug is
another viable solution.
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Biological half life
The goal of an oral sustained release product is to maintain therapeutic blood
levels  over  an  extended  period.  To  this,  drug  must  enter  the  circulation  at
approximately  the  same  rate  at  which  it  is  eliminated.  The  elimination  rate  is
quantitatively  described  by  the  half-life.  Each  drug  has  its  own  characteristic
elimination rate, which is the sum of all elimination processes including metabolism,
urinary excretion and all other processes that permanently remove drug from blood
stream.
Drugs  with  short  half-life  are  excellent  candidates  for  sustained-release
preparations,  since  this  can  reduce  dosage  frequency.  But,  drugs  with  very  short
biological half life require excessively large amounts of drug to maintain sustained
effect, forcing the dosage form itself to become large.
Drugs with half-life less than 2 hrs are poor candidates for sustained release
preparations. Drugs with long half-life, more than 8 hrs, are also generally not used in
sustaining forms, since their effect is already sustained but small dose size of drug can
prepare sustained form for reducing there side effect and give prolong action.
Side effects and safety considerations
There  are  very  few  drugs  whose  specific  therapeutic  concentrations  are
known.  Instead,  a  therapeutic  concentration  range  is  listed,  with  increasing  toxic
effects  expected  above  this  range  and  a  fall  off  in  desired  therapeutic  response
observed below the range. 
TI = TD 50 / ED50
                      Where, 
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TD50 = median toxic dose 
ED50 = median effective dose.
For potent drugs, the value of TI is small. Larger the value of TI, safer the
drug.  Drugs  with very small  value of TI  are poor candidates  for  formulation into
controlled-release product. A drug is considered to be relatively safe if its TI value
exceeds 10.
Dose Size
Generally, controlled-release systems will contain greater amount of drug than
a  corresponding  conventional  dosage  form.  For  those  drugs  requiring  large
conventional  doses,  the  volume  of  the  sustained  dose  may  be  so  large  as  to  be
impractical  or  unacceptable.  The same may be  true  for  drugs that  require  a  large
release rate from the controlled-release system, e.g. drugs with shorter half-life and
small dose size like 0.5 -10 mg.
Monolithic matrix delivery systems.
These systems can be considered as two groups (M.E. Aulton, 2000).
 Those with drug particles dispersed in a soluble matrix, with drug becoming
available as the matrix dissolves or swells and dissolves  (hydrophilic colloid
matrices)
 Those  with  drug  particles  dispersed  in  an  insoluble  matrix,  with  drug
becoming available as a solvent enters the matrix and dissolves the particles
(lipid matrices and insoluble polymer matrices)
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 Lipid matrix systems
 The active compound is contained in a hydrophobic matrix (wax) that remains
intact  during drug release.  Release depends on an aqueous medium dissolving the
channelling agent, which leaches out of the compact so forming a porous matrix of
tortuous capillaries. The active agent dissolves in the aqueous medium and, by way of
the water-filled capillaries, diffuses out of the matrix. These matrices are not now in
common usage, but the concept is worth considering. 
Insoluble polymer matrix systems
An inert matrix system is one in which a drug is embedded in an inert polymer
which is not soluble in the gastrointestinal fluids. Drug release from inert matrices has
been  compared  to  the  leaching from a  sponge.  The release  rate  depends  on  drug
molecules  in  aqueous  solution  diffusing  through  a  network  of  capillaries  formed
between  compacted  polymer  particles.This  type  of  delivery  system  would  not  be
suitable for the release of compounds that are insoluble or which have a low aqueous
solubility. 
 Hydrophilic colloid matrix systems
These delivery systems are also called swellable soluble matrices. In general
they  comprise  a  compressed  mixture  of  drug  and  water-swellable  hydrophilic
polymer. The systems are capable of swelling, followed by gel formation erosion and
dissolution in aqueous media. Their behaviour is in contrast to a true hydrogel, which
swells on hydration but does not dissolve.
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Principle of design of hydrophilic matrices
The  system  comprises  a  mixture  of  drug,  hydrophilic  colloid,  any  release
modifiers  and  lubricant/glidant.  On  contact  with  water  the  hydrophilic  colloid
components  swell  to  form a hydrated  matrix  layer.  This  then controls  the further
diffusion of water into the matrix. Diffusion of the drug through the hydrated matrix
layer  controls  its  rate  of  release.  The outer  hydrated  matrix  layer  will  erode as  it
becomes more dilute; the rate of erosion depends on the nature of the colloid. 
Hydrophilic colloid gels can be regarded as a network of polymer fibrils that
interlink in some way. There is also a continuous phase in the interstices between the
fibrils through which the drug diffuses.  These interstices  connect  together  and are
analogous to the tortuous capillaries seen in wax matrices. 
The tortuosity of the diffusion path and the 'microviscosity' and interactions
within the interstitial continuum govern the diffusion of the drug through the hydrated
gel layer, and hence the release of the drug.
Types of hydrophilic matrix
There are two types of hydrophilic matrix systems. They are
 True gels
 Viscous or 'Viscolized' matrices
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True gels
 These  systems  interact  in  the  presence  of  water  to  form  a  crosslinked
polymeric  structure  with  a  continuous  phase  trapped  in  the  interstices  of  the  gel
network. The crosslinks are more than just random hydrogen bonds between adjacent
polymer chains (e.g. alginic acid in the presence of di or trivalent cations, gelatin):
here they limit the mobility of the polymer chains and give a structure to the gel. The
crosslinks can be chemical bonds or physical  bonds, e.g. triple-helix formations in
gelatin gels which are based on hydrogen bonds. The portions of the polymer chains
between crosslinks can move, but the crosslinks restrict the overall movement of the
chains.
Viscous or 'Viscolized' matrices
Not all  matrix  systems  form 'true'  gels:  in  reality  some are  more  properly
described as very viscous solutions. In the presence of water these systems form a
matrix in which the increased viscosity occurs as a result of simple entanglement of
adjacent polymer chains, but without proper crosslinking. It is a dynamic structure.
The chains are able to move relative to one another and the drug diffuses through the
interstitial  continuum,  but  the  pathway is  not  fixed.  Examples  are  hydroxypropyl
methylcellulose and sodium alginate in water.
Advantages of hydrophilic matrix systems
 Comparatively simple concept
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 Excipients are generally cheap and are usually GRAS (generally regarded as
safe)
 Capable of sustaining high drug loadings
 Erodible, so reducing the possibility of 'ghost' matrices
 Easy  to  manufacture  using  commonly  available  equipment,  by  direct
compression, wet granulation or roller compaction
 Well established technology
 Uses readily available pharmaceutical manufacturing equipment
 Possible to obtain different  types  of release  profile:  zero order,  first  order,
biomodal etc.
Disadvantages of hydrophilic matrix delivery systems
 Release of the drug is dependent on two diffusion processes, penetration of the
water through the hydrated matrix into the nonhydrated core, and diffusion of
the dissolved drug through the hydrated matrix.
 If the outer layer of the hydrated matrix erodes, this can complicate the release
profile.
 Requires  batch-to-batch  consistency  in  the  matrix-forming  materials,  other
components and process parameters.
 Scale-up of manufacture can be a problem.
 Need optimal rate-controlling polymers for different actives.
These  matrices  are  comparatively  simple  in  concept.  However,  the  events
following hydration can be quite complex. The key is that there are two diffusion
processes (water in and then drug out). The drug will only diffuse through a hydrated
gel layer. This really only applies to drugs that are solid at room temperature. Liquid
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drugs may diffuse in the non-hydrated state and would not be suitable for some types
of system.
Components of hydrophilic matrix delivery systems
 Active drug
 Hydrophilic colloids
 Matrix modifier
 Solubilizer and/or pH modifier
 Compression aid
 Lubricant/ Glident.
Those components listed in parentheses are optional and not always necessary.
Matrix-forming agents for hydrophilic matrices
Hydrophilic colloids are which on contact with water form a hydrated gel that
remains  'sufficiently  intact'  during  passage  through  the  gastrointestinal  tract  are
suitable matrix-forming agents for hydrophilic matrices.
 Examples
Hydroxypropylmethylcellulose,Sodiumcarboxymethylcellulose,Alginates,
Xanthum  gum/locust  bean  gum  combinations,  Carbopol.  These  agents  generally
occupy 20-80% of  the  mass;  the  actual  amount  will  depend  on the drug  and  the
desired  release  characteristics.  Hydration  and  swelling  are  the  key  factors  in  the
functioning of a hydrophilic matrix, as has already been stated.
Gel modifiers for hydrophilic matrix delivery systems
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These  are  materials  that  are  incorporated  into  the  matrix  to  modify  the
diffusional characteristics of the gel layer, very often to enhance drug diffusion and
hence release of the drug. Examples include sugars, polyols and soluble salts. 
The type of modifier will depend very much on the chemical nature of the
hydrocolloids used. They may also modify the rate and extent of hydration of the
hydrophilic matrix material.Gel modifiers can have a number of other functions.
 To allow more complete, more uniform hydration of the gel matrix
 To allow more rapid hydration of the gel matrix
 To associate with the matrix molecules and thus to influence the interactions at
a molecular level, e.g. crosslinking.
 To modify the environment in the interstices of the gel, either to speed up or
slow down diffusion.
 To suppress or promote the ionization of ionizable polymers.
Solubilizers and pH modifiers for drugs in hydrophilic matrices 
Many drugs will  not dissolve sufficiently in gastrointestinal  fluids to allow
them to be released from a hydrophilic colloid matrix. Dissolution can be improved
by the inclusion of solubilizing agents (e.g. PEGs, polyols, surfactants etc.). The only
restriction is that the formulation can be formed into a tablet and that the material is
acceptable. Many drugs are ionizable. The inclusion of appropriate counter-ions can
facilitate release from the system. Some materials can act as both dissolution enhancer
and  matrix  modifier:  the  amount  of  excipient  needed  will  be  determined  by  the
amount  of  drug.The  above  relates  to  the  drug  molecule,  rather  than  the  matrix
material.  It  is necessary for any drug to be in solution for diffusion to occur.  For
insoluble drugs, solubilization is therefore an important consideration. With some gel
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materials the use of certain ions causes changes in the nature of the gel matrix. The
solubilizers and pH modifiers might also influence the release process through a direct
effect on the matrix. Different materials could augment crosslinking, whereas others
might perhaps weaken the crosslinks.
Lubricants for hydrophilic delivery systems
 As with any tablet compacted on a tablet machine, a lubricant is necessary.
Lubricants can have four functions:
1. Reduce inter particulate friction during compression and compaction
2. Reduce die-wall friction
3. Prevent sticking to the punches
4. Improve flow of the formulation on to the machine and into the die.
The requirement for lubricants for hydrophilic matrix tablets are no different
from those  for  any other  tablet,  and are  thus analogous to  those  for  conventional
immediate-release tablets and capsules. Generally the choice is not governed by the
same  constraints  as  in  immediate  release.  For  example,  over  blending  or  excess
magnesium stearate  may not be a  major  problem here.  It  is  not  essential  that  the
lubricant is soluble. Such lubricants are available but are generally not very effective
and tend to be reserved for effervescent products.
Suitable lubricants to be included in the formulation are listed below.
Hydrophobic lubricants
 Magnesium stearate.
 Calcium stearate.
 Stearic acid.
 Hydrogenated vegetable oil.
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Hydrophilic lubricants
 Glceryl palmitostearate
 Glyceryl behenate
 Sodium stearyl fumarate
 
Drug release from hydrophilic colloid matrices
 The classic  description of  the events  following immersion  of  a  matrix  in
aqueous media is as follows:
 Surface drug (if water soluble) dissolves and gives a 'burst effect'.
 The hydrophilic polymer hydrates and an outer gel layer forms.
 Gel layer becomes a barrier to uptake of further water and to the transfer drug.
 Drug (if soluble) release occurs by diffusion through the gel layer; insoluble
drug is released by erosion followed by dissolution.
 Following erosion the new surface becomes hydrated and forms a new gel layer.
 It may be anticipated that the relative importance of each release mechanism
will depend on the physicochemical properties of the gel layer; the aqueous solubility
of the drug; and the mechanical attrition of the matrix in the aqueous environment. 
When a drug/glassy polymer matrix is placed in an aqueous environment, the
water penetrates the polymer network. The intake of solvent (water) induces stresses
within the matrix polymer. Eventually the matrix polymer relaxes, and this manifests
itself as swelling. It is possible to differentiate three 'fronts' during hydration: eroding,
diffusing and swelling.
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The “swelling  front”  separates  the  rubbery  region  (swelling polymer  area)
which has enough water absorbed within the polymer to lower the Tg of the polymer
below  the  respective  environmental  temperature  allowing  for  macromolecular
mobility  and  swelling,  from the  non-swelling polymer  region  (where  the  polymer
exhibits a Tg that is above the respective environmental temperature).
 
 The “erosion front” separates the matrix from the bulk solution and is the
interface between the unstirred layer with polymer concentration gradient and the well
stirred medium.  The “diffusion front” is between the swelling and erosion front and
separated the areas of non dissolved drug from the area of dissolved drug. 
Figure 3: Pattern of drug release from the hydrophilic colloid matrices
The actual drug release mechanism depends on the relative contributions of
swelling and dissolution. Drug release from swellable, soluble matrices is constant
when swelling and eroding fronts synchronize, but is non-linear when this is not the
case.
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The release of sodium diclofenac from PVA and from HPMC matrices has
been  investigated.  It  was  noted  that  if  the  fronts  synchronized  then  the  gel  layer
thickness was constant and zero-order release was observed. When synchronization
did  not  take  place  the  gel  layer  tended  to  increase  in  thickness  and  there  was  a
decrease in the amount released, providing non-linear kinetics.
Matrix tablet.
One  of  the  least  complicated  approaches  to  the  manufacture  of  sustained
release  dosage  forms involves  the direct  compression of  blends of drug,  retardant
material, and additives to form a tablet in which drug is embedded in a matrix core of
retardant (Lachman L, 1990).
 Materials used as retardants in matrix tablet formulations.
There are three classes of materials used as release retardants in matrix tablet
formulations viz:
1) Insoluble inert polymers
Tablets prepared from these materials are designed to be ingested intact and
not break apart in GI tract. Ingested tablets contain unreleased drug in the core.
e.g.   Polyethylene, Poly vinyl chloride, Ethyl cellulose
         Methyl acrylate – methacrylate copolymer.
2) Insoluble, erodable polymers 
These  form  matrices  that  control  release  through  both  pore  diffusion  and
erosion.  Release  characteristics  are  therefore  more  sensitive  to  digestive  fluid
composition than to the totally insoluble polymer matrix. Total release of drug from
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wax-lipid matrices is not possible, since a certain fraction of the dose is coated with
impermeable wax films.
 e.g. Carnuba wax in combination with stearic acid, stearyl alcohol, Castor wax & 
Triglycerides
3) Hydrophilic polymers 
This group represents  non-digestable materials that  form gels  in situ.  Drug
release  is  controlled  by  penetration  of  water  through  a  gel  layer  produced  by
hydration of the polymer and diffusion of drug through the swollen, hydrated matrix,
in addition to erosion of the gelled layer.  The extent to which diffusion or erosion
controls release depends on the polymer selected for formulation as well as on drug:
polymer ratio.
Eg:   Methyl cellulose, Hydroxy ethyl cellulose, Hydroxypropylmethylcellulose, 
 Sodium alginate.
Types of Matrix Tablets 
There are three Types of Matrix Tablets
1. Hydrophilic matrices
2. Fat wax matrices
3. Plastic matrices
1. Hydrophilic matrix tablets
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 e.g. Sodium Carboxy-methylcellulose, Methylcellulose, HPMC 
Hydroxylethylcellulose, Polyethylene Oxide, Poly Vinyl Pyrrolidine, Poly Vinyl 
Acetate, Gelatin, Natural Gums etc.
Several commercial patented hydrophilic matrix systems are currently in use,
such as synchron technology and hydrodynamically balanced system.
Advantages
 Ease of manufacture.
 Excellent uniformity of matrix tablet
2. Fat wax matrix tablets
The drug can be incorporated into fat wax granulations by spray congealing in
air, blend congealing in an aqueous media with or without the aid of surfactants and
spray drying techniques.
e.g.  Polyethylene,  Ethyl  Cellulose,  Glyceryl  Esters of Hydrogenated Resins
has been added to modify the drug release pattern.
3. Plastic matrix tablets
                      e.g.Polyvinyl  chloride, Polyethylene, Vinyl Acetate, Vinyl Chloride
 copolymer, Vinyllidine chloride, Acrylate (or) Methyl methacrylate polymer, Ethyl c
ellulose, Cellulose acetate, Polystyrene.
With plastic material(s) tablets can be easily prepared by direct compression
of drug provided the plastic  material  can be communited or granulated  to desired
particle size to facilitate mixing with drug particles. 
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Polymers used in Matrix Tablets
The present study focuses on oral controlled-release dosage forms and types of
various polymers used to formulate matrix tablets. The use of polymers in controlling
the release  of  drugs  has  become important  in the  formulation of  pharmaceuticals.
Water soluble polymers such as polyethylene glycol and polyvinyl pyrrolidone may
be used to increase the dissolution rates of poorly soluble drugs. Hydrogels provide
the  basis  for  implantation,  transdermal  and  oral  controlled  release  systems.
Hydroxypropyl methylcellulose (HPMC) is cellulose ether which may be used as the
basis for hydrophilic matrices for controlled release oral delivery.
Hydrogel
 Polyhydroxyethyle methylacrylate (PHEMA) 
 Cross-linked polyvinyl alcohol (PVA) 
 Cross-linked polyvinyl pyrrolidone (PVP) 
 Polyethylene oxide (PEO) 
 Polyacrylamide (PA)
Soluble polymers
 Polyethylene glycol (PEG) 
 Polyvinyl alcohol (PVA) 
 Polyvinyl pyrrolidone (PVP) 
 Hydroxypropyl methyl cellulose (HPMC) 
Biodegradable polymers
 Polylactic acid (PLA) 
 Polyglycolic acid (PGA) 
 Polycaprolactone (PCL) 
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 Polyanhydrides 
Nonbiodegradable polymers
 Polyethylene vinyl acetate (PVA) 
 Polydimethyl siloxane (PDS) 
 Polyether urethane (PEU) 
 Polyvinyl chloride (PVC) 
 Cellulose acetate (CA) 
 Ethyl cellulose (EC) 
Mucoadhesive polymers
 Polycarbophil 
 Sodium carboxymethyl cellulose 
 Polyacrylic acid 
 Tragacanth 
 Methyl cellulose 
 Pectin 
Natural gums
 Xanthan gum 
 Guar gum 
 Karaya gum 
The matrix system is commonly used for manufacturing dosage forms because
it  makes  manufacturing  easy.  Sustained  release  tablets  are  formulated  so  that  the
active  ingredient  is  embedded  in  the  matrix  insoluble  substance.  So,  that  the
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dissolving drug has  to  find its  way out  through the holes  in  the  matrix.  In  some
sustained release formulation the matrix physically swell up, to form gel, so that the
drug has first dissolve in matrix, then exit through the outer surface.
 Direct compression.
 
There are a few crystalline substances,  such as sodium chloride,  potassium
chloride, that may be compressed directly. The vast majority of the drugs are rarely
easy to tablet due to poor compressibility and/or flowability. The use of compressible
diluents  and flow modulators  makes this  process  the most  streamlined  method of
tablet manufacture (Sandip Tiwari, 2003)
 Directly compressible vehicles
Definition 
A directly compressible diluent is an inert substance that may be compacted
with little difficulty and may compress even when quantities of drugs mixed with it. 
Compression capacity is still maintained when other tablet materials necessary
for flow, disintegration, and so forth are blended in. 
Requirements 
1) Good flow and compressibility
2) Inert
3) Tasteless
4) Reworkable
5) Able to disintegrate
6) Inexpensive.
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 Definition 
The term direct compression is used to define the process by which tablets are
compressed  directly  from  the  powder  blends  of  active  ingredients  and  suitable
excipients  (including filler,  disintegrant  and lubricants)  which will  flow uniformly
into the die cavity and form into a firm compact. No pretreatment of powder blend by
wet  or  dry granulation  procedure  is  necessary.  Occasionally  potent  drugs  will  be
sprayed out of solution into one of the excipients.
The advantages of direct compression were made possible by the commercial
availability  of  direct  compressible  tablet  vehicles  that  possess  both  fluidity  and
compressibility. The first such vehicle was spray dried lactose, which although it was
subsequently  shown  to  have  short  comings  in  terms  of  compressibility  and  color
stability, initiated the “direct compression revolution”.
 Lactose monohydrate (pharmatose 200 M, DCL-11, DCL-21 and DCL-25)
is the first effective filler.
 Other e.g.  Starch 1500; A partially pregelatinized starch  that  possesses  a
higher degree of flowability and compressibility. Encompress a free flowing
compressible dicalcium phosphate. Nutab, Di–Pac Compressible sugars.
For carrying out  direct  compression major advantages  were made in tablet
compression machinery,  such as improved positive die feeding and precompression
stages that facilitate direct compression tableting.
Advantages
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 Economy
 Reduced processing time
 Reduced labour time
 Fewer manufacturing steps
 Elimination of heat and moisture
 Better stability
 Uniformity in particle size
 Good compatibility property.
Disadvantages
 There  is  need  to  set  functionality  specifications  on  properties  such  as
compressibility  and  fluidity  as  well  as  more  traditional  physical  and
chemical properties.
 Not suitable for drugs characterized by high dose, high bulk volume, poor
compressibility and poor fluidity.
 Limitation in coloring tablets prepared by direct compression.
 Choice of excipients for their properties is extremely critical in formulating
direct compression tablets.
 Direct  compression  blends  are  subject  to  unblending  in  post  blending
handling steps. The lack of moisture in the blends may give rise to static
charges which can lead to unblending.
 Dust generation is more. 
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Release from matrix device
Matrix  delivery  system  are  of  two  types  diffusion/swellable  system,  and
dissolution  system In  diffusion  systems,  drug  release  is  mainly  governed  by  the
hydration of matrices,  followed by diffusion of drug molecules  from the hydrated
layer  to  the  surrounding  bulk  layer  of  solution,  and  sometimes,  partially  by  the
erosion/dissolution. Examples include Eudragit and cellulose ethers. With dissolution
systems, drug release is mainly due to dissolution/erosion of the matrix and hence,
achievement  of  constant  drug  delivery  rate  is  easier  by  these  systems.  Sodium
carboxymethylcellulose and natural gums are examples of polymers that are gaining
popularity in matrix drug delivery systems.
Drug from matrix may be diffusion, erosion and swelling which may vary
molecular size of polymer, nature of polymer, polymer ratio, compounds of polymer
etc. have their impact on the release of drug from matrix it may be either diffusion, or
erosion and swelling.
Mechanism of drug release from hydrophilic matrix tablets 
The mechanism of drug release from hydrophilic matrix tablets after ingestion
is complex but it is based on diffusion of the drug through, and erosion of, the outer
hydrated polymer on the surface of the matrix. Typically, when the matrix tablet is
exposed to an aqueous solution or gastrointestinal fluids, the surface of the tablet is
wetted and the polymer hydrates to form a Gelly-like structure around the matrix,
which is referred to as the “gel layer”. This process is also termed as the glassy to
rubbery state transition of the (surface layer) polymer. This leads to relaxation and
swelling of the matrix which also contributes to the mechanism of drug release. The
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core of the tablet remains essentially dry at this stage. In the case of a highly soluble
drug, this phenomenon may lead to an initial burst release due to the presence of the
drug on the surface of the matrix tablet. The gel layer (rubbery state) grows with time
as more water permeates into the core of the matrix, thereby increasing the thickness
of the gel layer and providing a diffusion barrier to drug release. Simultaneously, as
the  outer  layer  becomes  fully  hydrated,  the  polymer  chains  become  completely
relaxed and can no longer maintain the integrity of the gel layer, thereby leading to
disentanglement and erosion of the surface of the matrix. Water continues to penetrate
towards  the core of  the tablet,  through the gel  layer,  until  it  has been completely
eroded.  Soluble drugs  can  be  released  by a  combination of  diffusion and erosion
mechanisms whereas erosion is the predominant mechanism for insoluble drugs. For
successful extended release of drugs, it is essential that polymer hydration and surface
gel  layer  formation are quick so as to prevent  immediate tablet disintegration and
premature drug release. For this reason, polymers for hydrophilic matrices are usually
supplied in small particle size to ensure rapid hydration and consistent formation of
the gel layer on the surface of the tablet. A large number of mathematical models have
been developed to describe drug release profiles from matrices. The simple and more
widely used model is the one derived by Korsmeyer et al. and is as follows:
Mt / Mα = k t n -------------------------------- (1)
where Mt / Ma is the fraction of drug release, k is the diffusion rate constant, t
is the release time and n is the release exponent indicative of the mechanism of drug
release. The equation was modified by Ford et al. to account for any lag time or initial
burst release of the drug
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Mt / Ma = k (t – 1) n------------------------------ (2)
Where l  = lag time. It is clear from both equations that when the exponent n
takes  a  value  of  1.0,  the  drug  release  rate  is  independent  of  time.  This  case
corresponds to zero-order release kinetics (also termed as case II transport). Here, the
polymer relaxation and erosion are the rate-controlling steps. When n = 0.5, Fickian
diffusion is the rate-controlling step (case I transport). Values of n between 0.5 and 1
indicate the contribution of both the diffusion process as well as polymer relaxation in
controlling  the  release  kinetics  (non-Fickian,  anomalous  or  first-order  release).  It
should be noted that the two extreme values of n = 0.5 and 1 are only valid for slab
geometry. For cylindrical tablets, these values range from 0.45 < n < 0.89 for Fickian,
anomalous or case II transport respectively.
1.4. Angina pectoris
Angina  pectoris,  commonly  known  as angina,  is  severe chest  pain due
to ischemia (a  lack  of  blood,  hence  a  lack  of oxygen supply)  of  the heart  muscle,
generally  due  to  obstruction  or  spasm  of  the coronary  arteries. Coronary  artery
disease, the main cause of angina, is due to atherosclerosis of the cardiac arteries. The
term  derives  from  the Latin angina ("infection  of  the  throat")  from  the  Greek 
ἀγχόνη  ankhone  ("strangling"), and the Latin pectus ("chest"), and can therefore be
translated as "a strangling feeling in the chest".
Types of angina pectoris
Stable angina
   Stable angina is a repeating pattern of chest pain which has not changed in
character, frequency, intensity or duration for several weeks. The level of activity or
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stress  that  provokes  angina  is  predictable  and  the  pattern  changes  slowly.  Stable
angina is the most common form and it appears gradually.  These patients have an
increased risk of a heart attack, but an episode of stable angina does not indicate that a
heart attack is about to happen. 
Pathology
Severe  arteriosclerotic  affliction  of  larger  coronary  arteries.  Which  run
epicardially and send perforating branches to supply the deeper tissue. The coronary
obstructions are fixed, blood flow fails to increase during increased demand despite
local factors mediated dilatation of resistance vessels and ischemic pain is felt. Thus a
form of acutely developing and rapidly reversible left ventricular failure results which
is relieved by taking rest and reducing the myocardial work load (KD. Tripathi, 2008).
Unstable angina
Unstable angina is chest pain that is variable, either increasing in frequency or
intensity and with irregular timing or duration. Unlike stable angina, unstable angina
does not appear gradually, it first appears as a severe episode (KD. Tripathi, 2008).
An established stable angina might change suddenly or be provoked by less stress
than in the past or an episode might suddenly occur while at rest. If the pattern of an
episode  changes,  for  example  if  a  previous  episode  was  only  brought  on  during
physical exertion, but an episode suddenly occurred at rest it is likely to be unstable
angina.
Prinzmetal's angina 
Prinzmetal’s  or  variant  angina  is  caused  by  a  vasospasm,  a  spasm  that
narrows  the coronary  artery  and  lessens  the  blood  flow to  the heart.  Prinzmetal's
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Angina usually occurs in arteries already narrowed by atherosclerosis; in fact most
people with it have severe coronary.
Mechanism of relief of angina
The dilator effect on larger coronary vessels is the principal action of nitrates
benefiting  variant  angina  by  counter  acting  coronary  spasm.  In  classical  angina
undoubtedly the primary effect  is  to  reduce  cardiac  work by action  on peripheral
vasculature, though increased blood supply to ischemic area may contribute. Exercise
tolerance of angina patients is increased because the same amount of exercise causes
lesser augmentation of cardiac work.
Figure 4: Dysfunction of heart due to Angina pectoris
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What causes angina?
The most common cause of angina is coronary artery disease. A less common
cause of angina is spasm of the coronary arteries.
Coronary artery disease
Coronary  arteries  supply  oxygenated  blood  to  the  heart  muscle.  Coronary
artery  disease  develops  as cholesterol is  deposited  in  the  artery  wall,  causing  the
formation of a hard, thick substance called cholesterol plaque. The accumulation of
cholesterol  plaque  over  time causes  narrowing of  the coronary arteries,  a  process
called  arteriosclerosis.  Arteriosclerosis  can  be  accelerated  bysmoking, high  blood
pressure, elevated cholesterol, and diabetes. When coronary arteries become narrowed
by more than 50% to 70%, they can  no longer  meet  the  increased  blood oxygen
demand by the heart  muscle during exercise or stress.  Lack  of oxygen  to the heart
muscle causes chest pain (angina).
Coronary artery spasm
The walls of the arteries are surrounded by muscle fibers. Rapid contraction of
these muscle fibers causes a sudden narrowing (spasm) of the arteries. A spasm of the
coronary arteries reduces blood to the heart muscle and causes angina. Angina as a
result  of  a  coronary artery spasm is  called "variant"  angina  or  Prinzmetal  angina.
Prinzmetal angina typically occurs at rest, usually in the early morning hours. Spasms
can occur in normal coronary arteries as well as in those narrowed by arteriosclerosis.
Coronary artery spasm can also be caused by use/abuse of cocaine. The spasm of the
artery wall caused by cocaine can be so significant that it can actually cause a heart
attack.
Treatment of angina pectoris:
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The main goals of treatment in angina pectoris are relief of symptoms, slowing
progression of the disease, and reduction of future events, especially heart attacks and
of  course  death.  An  aspirin  (75  mg  to  100  mg)  per  day  has  been  shown  to  be
beneficial for all patients with stable angina that have no problems with its use. Beta
blocker (eg. Carvedilol, Propranolol and Atenolol etc are few examples) have a large
body of evidence in morbidity and mortality benefits (fewer symptoms and disability
and live longer) and short-acting nitroglycerin medications are used for symptomatic
relief  of  angina.  Calcium channel  blockers  (such  as  Nifedipine and  Amlodipine),
Isosorbide mononitrate and  Nicorandil are vasodilators commonly used in chronic
stable angina.  A new therapeutic  class, called If  inhibitor,  has recently been made
available:  Ivabradine provides  pure  heart  rate  reduction,.[1] Leading  to  major  anti-
ischemic  and antianginal  efficacy.  ACE inhibitors are  also vasodilators  with  both
symptomati  prognostic  benefit  and  lastly,  statins are  the  most  frequently  used
lipid/cholesterol modifiers which probably also stabilise existing atheromatous plaqu
Nitrates 
Short Acting: Glyceryl trinitrate (GTN, Nitroglycerine)
Long Acting: Isosorbide dinitrate (short acting by sublingual route), Isosorbide
mononitrate, Erythrityl tetranitrate, Penta erythritol tetranitrate.
ß-Blockers
Propranolol, Metoprolol, Atenolol and others.
Calcium Channel Blockers
Phenyl Alkylamine: Verapamil
Benzothiazepine: Diltiazem
Dihydropyridines: Nifedipine, Felodipine, Amlodipine, Nitrendipine, 
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Nimodipine, Lacidipine.
 Potassium Channel Opener
 Nicorandil, Penacidil and Dizoxide
 Others
Dipyridamole, Trimetazidine, Oxyphedrine. 
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2. LITERATURE REVIEW
Anil Kumar. SN et al., (2010) the aim of the present study is to develop colon 
targeted drug delivery systems for Trimetazidine Hcl using sodium alginate as a carrier. 
In this study, investigation of an oral colon specific, pulsatile device to achieve time or 
site specific release of Trimetazidine, based on chronopharmaceutical considerations. The
basic design consists of an insoluble hard gelatin capsule body, filled with sodium 
alginate microsphere of trimetazidine and sealed with a hydrogel plug. The entire device 
was enteric coated, so that the variability in gastric emptying time can be overcome and a
colon-specific release can be achieved. Different concentration of the hydrogel polymers 
were used as plugs, to maintain a suitable lag period and it was found that the drug 
release was controlled by the proportion of polymers used. FTIR study confirmed that 
there was no interaction between drug and polymer, the shape of microsphere was 
foundto be spherical by SEM studies. In vitro release studies of pulsatile device revealed 
that, increasing the hydrophilic polymer content resulted in delayed release of 
trimetazidine from microspheres.
Abhijit N. Merekar et al., (2010) monolithic matrix tablets of Trimetazidine 
Dihydrochloride were formulated as modified release tablet employing hydroxy propyl 
methyl cellulose polymer, and the modified release behavior of fabricated tablets was 
investigated. Modified released matrix tablets contain 35.7 mg Trimetazidine 
Dihydrochloride  were developed using different drug polymer concentration of H. P. M. 
C. Tablets were prepared by wet granulation using I.P.A. Formulation was optimized on 
the basis of acceptable tablet properties and in vitro drug release.. All tablets but one 
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exhibited gradual and near completion modified release for Trimetazidine 
Dihydrochloride, and 98.5 to 101.5% released at the end of 8 h. An increase in release 
kineticsof the drug was observed on decreasing polymer concentration.
Basu S.K et al., (2010) microspheres of Trimetazidine Hydrochloride (TZ) were 
prepared by coacervation method without the use of chemical cross–linking agents such 
as glutaraldehyde to avoid the toxic reactions and other undesirable effects of the 
chemical cross-linking agents. Alternatively, ionotropic gelation was employed by using 
sodium-tripolyphosphate (Na-TPP) as cross linking agent. Chitosan was used as polymer.
All the prepared microspheres were subjected in-vitro drug release characteristics and 
release kinetics. TLC and FTIR studies indicated no drug-polymer incompatibility. As the
drug to polymer ratio was increased, the mean particle size (MPS) of TZ microspheres 
was also increased. A maximum of 80% of drug entrapment efficiency was obtained by 
the method employed. All the MS showed zero order release kinetics followed by a 
Fickian diffusion mechanism. From the above data it was concluded that it may be 
possible to design a controlled drug delivery system for the prolonged release of TZ, 
improving therapy by possible reduction of time intervals between administrations.
Raj Kumar et al., (2010) the purpose of the present study was to formulate the 
oral controlled release Trimtazidine di hydrochloride tablets by using Polysaccharide B-
1459 (14-38%) as rate controlling polymer. The tablets were prepared by direct 
compression method and coated by the film coating polymers. The powder mixtures were
evaluated for angle of repose, loose bulk density, tapped bulk density and compressibility
index, shows satisfactory results. All the ingredients were lubricated and compressed 
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using 8mm circular shaped deep concave punches. Compressed tablets were evaluated for
uniformity of weight, content of active ingredient, thickness, friability, hardness and In-
vitro dissolution studies. The in vitro release study of matrix tablets were carried out in 
0.1N Hydrochloric acid with pH 1.2 for 10 hours. The prepared matrix tablets were 
shown 99.00%, 100.00%, 104.00%, 92.00% and 100.00% release over a period of 10 
hours. It was observed that the amount of polymer influences the drug release. In vitro 
release study results revealed that the release of drug was retarded with the proportional 
increase of the polymer concentration.
Punit B. Parejiya et al., (2010) formulated a Sustained release Aceclofenac 
matrix tablets constituting Kollidon SR (Polyvinyl acetatepovidone based matrix 
retarding polymer) were developed for manifesting desirable release profile. Matrix 
tablets were prepared by direct compression of Kollidon SR varying proportion with 
fixed percentage of aceclofenac. Tablets containing 50 % Kollidon SR demonstrated a 
rapid rate of drug release with an initial burst effect. Incorporation of more Kollidon SR 
in the tablet prolonged drug release with subsequent minimization of burst effect as 
confirmed by mean dissolution time, dissolution efficiency, f2 and drug release kinetic 
data. The formulation showed close resemblance to commercial product Senafen. The 
results were explored and explained by the difference of physico-chemical property and 
micromeritic characteristics. Insignificant effect of various factors e.g. pH, ionic strength,
paddle speed was found on drug release. The formulation followed Korsmeyer and 
peppas kinetic of drug release. Stability study data indicated stable character after short 
term stability study.
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Bhupendra et al., (2010) has revealed that the hydrophilic polymer (HPMC 
K200M) and hydrophobic polymer (EC, Eudragit RSPO) based Nicorandil matrix SR 
tablet which can release drug up to time of 24hrs. Hydrophilic and Hydrophobic polymer 
combination gives good result than alone hydrophilic or hydrophobic polymer is used.
Gothi G.D et al., 2010) in the present investigation an attempt was made to 
reduce the frequency of dose administration, to prevent nocturnal heart attack and to 
improve the patient compliance by developing extended release (ER) matrix tablet of 
metoprolol succinate. The effect of concentration of hydrophilic (hydroxypropyl 
methylcellulose [HPMC K 100 M], xanthan gum) on the release rate of metoprolol 
succinate was studied. Hydrophilic matrix tablets were prepared by wet granulation 
technique and evaluated for various parameters like, weight variation, content uniformity,
in-vitro dissolution. and in vitro dissolution studies were performed using United States 
Pharmacopeia (USP) apparatus type II. The drug release kinetics was found to be 
governing by the type of the amount of the polymer in the matrix system. The higher 
polymeric content in the matrix decrease the release rate of the drug. At lower polymeric 
level, the rate and extent of drug release were evaluated. All formulation showed 
compliance with pharmacopoeial standards. The studies indicated that the drug release 
can be modulated by varying the concentration of the polymer. Among the ten 
formulations, F9 best matched formulation with respect to market product. Optimized 
formulation was found stable during accelerated stability study for 3 months at 
400C/75% RH.
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Y Haung et al., (2009) developed and optimized the propranolol once-daily 
substained release formulations containing HPMC, Microcrystalline cellulose (MCC) and
lactose. In vitro studies, the response surface methodology and polynomial equation were
used to search for the optimal formulation with specific release rate at different time 
intervals. The constrained mixture experimental design was used to prepare systematic 
model formulations, which were composed of three formulation variables: the content of 
HPMC (X(1)) MCC (X(2)) and lactose (X(3)). The drug release percent at 1.5, 4, 8, 14 
and 24 h were the target responses and were restricted to 15-30, 35-55, 55-75, 75-90 and 
90-110%, respectively.
M. Ganesh, et al., (2009) was developed a new validated spectrophotometric 
method for determination of class III drug in Formulation and comparison with UV 
method.
A.Hamid et al., (2006) formulated and Evaluated of Once-Daily tablets of 
Cefpodoxime using hydroxypropyl methylcellulose. Tablets were prepared by direct 
compression. In vitro drug release was evaluated using USP Apparatus-II. It was found 
that 16.86% of the drug was released during the first hour. During the initial 9 hours, 
~50% of the drug was released. After 9 hours, the release rate increased slightly, until the 
21st hour, and then release slowed but continued until the 24-hour mark. Hence, the 
formulation can be considered as a once-daily sustained-release tablet of Cefpodoxime 
Proxetil.
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A Kuksal et al., (2006) prepared and characterized sustained-release matrix 
tablets of zidovudine using hydrophilic Eudragit RLPO and RSPO alone or their 
combination with hydrophobic ethyl cellulose. Release kinetics was evaluated by using 
(USP)-22 type I dissolution apparatus. The in vitro and in vivo newly formulated 
sustained--release zidovudine tablets were compared with conventional marketed. The in-
vitro drug release study revealed that either Eudragit. Preparation was able to sustain the 
drug release only for 6 hours (94.3% ± 4.5% release). Combining Eudragit with ethyl 
cellulose sustained the drug release for 12 hours (88.1% ± 4.1% release). Fitting the in 
vitro drug release data to Korsmeyer equation indicated that diffusion along with erosion 
could be the mechanism of drug release.
M. Harris shoaib et al., (2006) have been developed once-daily sustained release
matrix tablet of ibuprofen using hydroxypropyl methylcellulose (HPMC) as release 
controlling factor and to evaluate drug release parameters as per various release kinetic 
models. In order to achieve required sustained release profile tablets were directly 
compressed using Avicel pH 101 and Magnesium stearate. The formulated tablets were 
also characterized by physical and chemical parameters and results were found in 
acceptable limits. Different dissolution models were applied to drug release data in order 
to evaluate release mechanisms and kinetics. Criteria for selecting the most appropriate 
model were based on linearity (coefficient of correlation). The drug release data fit well 
to the Higuchi expression. Drug release mechanism was found as a complex mixture of 
diffusion, swelling and erosion.
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Gabriele Fragasso et al., (2006) reported that the long-term addition of Class III 
drug improves functional class and left ventricular function in patients with heart failure 
(HF).
2003) designed and evaluate a directly compressible 
hydrophilic poly(ethylene oxide) (PEO) matrix for the oral sustained delivery of 
dihydrocodeine bitartrate (DHCT). A direct compression method was used to prepare 
PEO matrices, and the amount of PEO in the matrices was varied to optimize in vitro 
DHCT release profiles. From the data obtained in this research, hydrophilic PEO matrices
were found to be a novel sustained-release carrier for the oral delivery.
David A. Fairman et al., (2003) reported the class III drug acts as an effective 
antianginal clinical agent by modulating cardiac energy metabolism. It selectively inhibits
long-chain 3-ketoacyl CoA thiolase (LC 3-KAT), there by reducing fatty acid oxidation 
resulting in clinical benefit.
YSR Krishnaiah et al., (2002) formulated “Three-layer guar gum matrix tablet 
formulations for oral controlled delivery of highly soluble class III drug” using guar gum 
as a carrier. Matrix tablet granules containing 30%, 40% or 50% of guar gum were 
prepared by the wet granulation technique using starch paste as a binder. The three-layer 
guar gum matrix tablet estimated using a HPLC method, provided the required release 
rate compare with the theoretical release rate for guar gum formulations meant for twice 
daily administration. The results indicated that guar gum, in the form of three-layer 
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matrix tablets, is a potential carrier in the design of oral controlled drug delivery systems 
for highly water-soluble drugs.
Gidwani, Prashant Kumar et al., (2002) designed sustained release matrix 
pharmaceutical compositions containing 60mg of class III drug  constituting 8 to 50% by 
weight of the composition and hydrophobic polymers as a retardant by hot melt 
granulation at a temperature of 40°C to 120°C, which release drug in a sustained and 
reproducible manner over 24 hour. The Diluent comprises 10 to 70% by weight of the 
composition such as calcium carbonate. Binder comprises 2 to 10% consisting of gelatin 
and gum acacia. Glidant comprises 0.5 to 1.5% by weight of the composition consisting 
of colloidal silicone dioxide. Lubricant comprises 0.5 to 1.0% by weight of the 
composition selected from magnesium stearate. The tablets were film coated with 0.5 to 
4.0% by weight of the tablet using cellulose derivatives. The dissolution was carried out 
in gastric simulated fluid pH 1.2 for the first hour and then in phosphate buffer pH 6.8 
USP.
Purushottam S et al., (2002). was developed sustained release matrix 
compositions containing 60 mg of Class III drug and hydrocolloid forming materials such
as HPMC, HPC, Povidone, SCMC, Sodium alginate, Polyvinyl alcohol, Xanthan gum. 
Hydrophobic polymers as a retardant which release drug in a sustained and reproducible 
manner over a prolonged period of time to achieve the sustained effect of drug over a 24 
hour period after oral administration.
. Tulsidutt et al., (2002)  designed sustained release matrix pharmaceutical 
compositions characterized by the absence of cellulose and/or their derivatives as release 
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modifying agent containing, class III drug constituting 8 to 50% by weight of total 
composition formulated either water soluble material such as Polyethylene oxide, Sodium
alginate, Calcium alginate and Xanthan Gum and water insoluble material such as stearic 
acid and polyvinyl acetate, or water swellable material such as guar gum, alginic acid.
Gilbert Regnier et al., (1994) reported that the Class III drug is useful for the 
treatment of ischeamic pathologies and peripheral vascular pathology.
Department of pharmaceutics                  48              JKKMMRF college of pharmacy
Chapter 3                                                                                        Aim & plan of work
3. AIM AND PLAN OF WORK
3.1. Aim
Oral ingestion has long been the most convenient and commonly employed
route  of  drug  delivery.  Indeed,  for  Extended  release  systems,  the  oral  route  of
administration  has  by far  received  the  most  attention  with respect  to  research  on
physiological and drug constraints as well as design and testing of products.
The primary objective of the extended release (Matrix) drug delivery system is
to ensure safety and to improve efficacy of drug as well as patient compliance.  The
present  invention  provides  a  novel  sustained  release  composition  comprising
Trimetazidine Dihydrochloride. The objective of the present study was to formulate
and  evaluate  once  daily  extended  release  matrix  tablets  of  Trimetazidine
Dihydrochloride using hydrophilic polymers Hydroxypropylmethylcellulose, Polyox,
and natural polymer Xanthan gum. 
  Trimetazidine has a half life 6 hrs and usual oral dosage regimen 0.5 mg and
60  mg  daily.  To  reduce  the  frequency  of  administration  and  to  improve  patient
compliance, a once-daily extended release formulation of Trimetazidine is desirable.
The most commonly used method of modulating the drug release is to include it in a
matrix  system.  Hydrophilic  polymer  matrix  systems  were  widely  used  in  oral
controlled  drug delivery because  they make it  easier  to  achieve  a desirable  drug-
release  profile,  they  are  cost  effective  and  they  have  broad  US  Food  and  Drug
Administration acceptance.
Hence,  in  present  work,  an  attempt  has  been  made to  develop  once  daily
sustained release matrix tablets of Trimetazidine using putative hydrophilic matrix
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materials. The drug release for extended duration using a hydrophilic matrix system is
restricted because of rapid diffusion of dissolved drug through the hydrophilic gel
network. For such circumstances,  hydrophobic polymers are suitable,  along with a
hydrophilic matrix for developing sustained release dosage forms. 
3.2. Plan of work
1) Literature Survey.
2) Innovator characterization. 
a) Physical evaluation.
b) Chemical evaluation.
3) Preformulation studies.
a) Compatibility studies with excipients.
b) Excipients selection.
c) API physical and chemical evaluation.
4) Formulation Development.
a) Process evaluation.
b) Formula evaluation.
c) Process optimization.
5) Formulation evaluation.
a) Physical evaluation.
b) Chemical evaluation.
6) Stability studies.
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4. MATERIALS AND METHODS
4.1. Materials used
The  materials  employed  in  the  formulation  and  evaluation  and  the
corresponding manufacturers were listed in the following table.
Table 1:  List of materials used in formulation development.
S.
No
Ingredient Manufacturer
1 Trimetazidine dihydrochloride Nivedita chemicals- Mumbai
2 Anhydrous calcium hydrogen phosphateBP/Ph.Eur Innophos inc- United States
3 Polyethylene oxide (Polyox WSR 301 LEO) NF Dow chemical's- Tamil Nadu
4 HPMC K 200 M BP/USP/Ph.Eur Dow chemical's- Tamil Nadu
5 Xanthan gum FF BP/Ph.Eur Lucid colloids ltd -Mumbai
6 Povidone BP/Ph.Eur (K90F) BASF –Germany
7 Colloidal Anhydrous Silica Deggusa
8 Magnesium stearate BP/Ph.Eur. Vijlak Pharma Ltd-Hyderabad
4.2. Equipment used
Table 2: Equipments used
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S.
No Name of equipment Manufacturer
1 Digital Weighing balance Essae digi
2 Vibratory Sifter Ganson / Anchor
3 Octagonal Blender Ganson / Bectochem
4 Tablet Compression machine Cadmach Machinery Pvt. Ltd
5 Vernier callipers Mitatoyo
6 Friability apparatus Electrolab
7 Hardness tester Varian
8 Six station dissolution tesapparatus Electro Lab
9 UV-Visible Spectrophotometer Shimadzu
10 Blister Packing Machine Ezee Blister
4.3. Drug and excipient profile
4.3.1. Drug Profile (European Pharmacopoeia, 2005)
Trimetazidine  Dihydrochloride
Figure 5: Structure of Trimetazidine dihydrochloride
   
Category: Antiangina.
Empirical Formula: C14H22N2O3.2HCl.   
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Chemical name: (2, 3, 4-Trimethoxybenzyl) piperazine dihydrochloride 
Trimetazidine Dihydrochloride contains not less than 98.5 percent and not more than 
101.5 per cent, calculated on the dried basis.
Molecular Weight: 339.26 g/mol.   
Appearance, odor and Color: White crystalline powder.o
Melting Point: Between 225o and 227o .
Identification: Identified by IR Spectrophotometer by KBr disc method.
 pKa:   pKa values 4.32 and 8.95 .
Solubility: Soluble in water, sparingly soluble in ethanol & practically insoluble in
ether.
Assay 
Dissolve 0.12g in 50.0 ml of water. Add 1 ml of nitric acid and titrate with
0.1M silver nitrate, determining the end point potentiometrically (2.4.25).Carry out a
blank  titration.  1  ml  of  0.1N  silver  nitrate  is  equivalent  to  0.011696  g  of
C14H24Cl2N2O3.
Pharmacokinetic data.
Bioavailability:  87%.
Metabolism:  Myocardial, free fatty acid.
Half life: 6 hrs.
Protein binding: 16%.
Excretion: Renal.
Pharmacodynamic properties 
Class III drug is a unique anti-ischemic drug, which protects the myocardial 
cell from the harmful effects of ischemia (M. Marzilli et al., 2001).
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 Mechanism of action
The mode of action is drug is different from beta-blockers, calcium channel
determinants of myocardial oxygen supply-demand balance; Class III drug prevents
the damage to the myocardial cell during an ischemic pisode. Drug inhibits fatty acid
oxidation secondary to an inhibition of long-chain 3-ketoacyl CoA thiolase (KAT),
resulting  in  an  increase  in  glucose  oxidation.  This  results  in  switching  energy
substrate preference from fatty acid oxidation to the more efficient glucose oxidation
which  explains  the  anti  anginal  properties.  Drug  prevents  intracellular  metabolic
changes such as  depletion of  adenosine triphosphate (ATP) and phosphocreatinine
accumulation  of  protons,  and  toxic  free  radical  generation  which  result  from
ischaemia and reperfusion in the myocardium.
 Clinical Pharmacology
Therapeutic Uses
 Trimetazidine dihydrochloride is indicated in the treatment of ischemic heart
disease (angina pectoris, sequelae of infarction).
Adverse reaction
The most commonly encountered side effects are gastric discomfort, nausea,
headache and vertigo. However, the side effects are mild and non-specific.
Drug interaction
No drug interactions have been reported.  In particular,  no interactions have
been reported with beta-blockers, calcium antagonists, nitrates, heparin and digitalis
preparation.
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Precautions
Renal and hepatic impairment
No  dosage  adjustments  are  required  in  patients  with  impaired  renal  and
hepatic function.
Pregnancy
There  is  insufficient  evidence  to  recommend  the  use  of  Class  III  drug  in
pregnancy.
Lactation
There is no information on the secretion of class III  drug into breast  milk.
However,  breast-feeding  should  be  discontinued  if  the  use  of  class  III  drug  is
considered  essential.  In  general,  use of  this  medication by nursing mothers  is  not
recommended.
Pediatric use
There is no data available for the use of class III drug in children.
Dosage
Adults: 60mg 1 time a day.
4.3.2. Polymer profile (Raymond C Rowe, 1995).
Hydroxy propyl methylcellulose
Synonyms: Benecel MHPC, methocel, metolose, Pharmacoat, spectracel, tylopur.
Chemical name: Cellulose, 2-Hydroxypropyl methyl ether.
Empirical formula: HPMC is a partly o-methylated and o- (2-hydroxypropylated).
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Figure 6: Structure of hydroxy propyl methyl cellulose
Molecular weight: Approx. 10000-1500000
Functional category 
Bioadhesive,  Emulsifying  agent,  release  modifying  agent,  sustained  release
agent, suspending agent, tablet binder, viscosity-increasing agent, film forming agent.
Description: Odorless, tasteless, white or creamy white fibrous or granular powder.
Aqueous viscosity: HPMC K 15   - 15000 mPas.
Solubility
 Soluble in cold water, insoluble in alcohol, ether and chloroform but soluble
in a mixture of methylene chloride and methanol.
Stability and storage condition 
Stable in  dry condition from pH 3.0 to  11.0 although it  is  hygroscopic  in
nature. Should be store in well closed container, in a cool and dry place.
Incompatibilities
 Incompatible  with  some  oxidizing  agents.  Since  it  is  nonionic,  hydroxy
methylcellulose will not complex with metallic effect.
Safety
 It’s  generally  regarded  as  a  nontoxic  and  non-irritant  material  although
excessive oral consumption may have a laxative effect.
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Application
 Depending upon the viscosity grade, concentrations of 2–20% w/w are used
for  film-forming solutions to film-coat tablets.  Lower viscosity grades  are used in
aqueous film-coating solutions, while higher-viscosity grades are used with organic
solvents. It is also used in extended release matrix.
Polyethylene oxide
Synonyms: Polyox; polyoxirane, polyoxyethylene.
Chemical name and cas registry number: Polyethylene oxide [25322-68-3].
Molecular weight: 4 000 000.
Structural formula
The USPNF 23 describes polyethylene oxide as a nonionic homopolymer of
ethylene  oxide,  represented  by the formula  (CH2CH2O)n,  where  n  represents  the
average number of oxyethylene groups. It may contain up to 3% of silicon dioxide.
Functional category: Mucoadhesive, tablet binder, thickening agent.
Applications in pharmaceutical formulation or technology
Polyethylene oxide can be used as a tablet binder at concentrations of 5–85%.
The higher molecular weight grades provide delayed drug release via the hydrophilic
matrix approach.
Description: White to off-white, free-flowing powder, slight ammonical odor.
Typical properties
Angle of repose              : 348
Density (true)                 : 1.3 g/cm3
Melting point                 : 65–70o C
Moisture content            : <1%
Solubility    
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 Polyethylene  oxide is  soluble in water  and a number of  common organic
solvents such as acetonitrile, chloroform, and methylene chloride. It  is insoluble in
aliphatic hydrocarbons, ethylene glycol, and most alcohols.(2) Viscosity (dynamic). 
Stability and storage conditions
Store in tightly sealed containers in a cool, dry place. Avoid exposure to high
temperatures since this can result in reduction in viscosity.
Incompatibilities
Polyethylene oxide is incompatible with strong oxidizing agents.
Safety
Animal studies suggest  that  polyethylene  oxide has a low level  of toxicity
regardless  of  the  route  of  administration.  It  is  poorly  absorbed  from  the
gastrointestinal tract but appears to be completely and rapidly eliminated. The resins
are neither skin irritants nor sensitizers, and they do not cause eye irritation.
Handling Precautions
Observe normal precautions appropriate to the circumstances and quantity of
material handled.
Regulatory Status
Included in the FDA Inactive  Ingredients  Guide (sustained release tablets).
Included in the Canadian List of Acceptable Non-medicinal Ingredients.
Xanthan gum
Synonyms  
Corn  sugar  gum,  E415,  Keltrol,  polysaccharide  B-1459, Rhodigel,  Vanzan
NF, Xantural.
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Chemical name: Xanthan gum.
Cas registry number:  [11138-66-2].
Molecular formula: (C35H49O29) n .
Description 
Xanthan gum occurs as a cream- or white-colored, odourless,  free-flowing,
fine powder.
Solubility 
Practically insoluble in ethanol and ether;, soluble in cold or warm water.
Viscosity 
1200–1600 mPas (1200–1600 cP) for a 1% w/v aqueous solution at 258°C.
Structural formula
Each xanthan gum repeat unit contains five sugar residues: two glucose, two
mannose,  and  one  glucuronic  acid.  The  polymer  backbone  consists  of  four  b-D-
glucose units linked at the 1 and 4 positions, and is therefore identical in structure to
cellulose. Trisaccharide side chains on alternating anhydroglucose units distinguish
xanthan from cellulose. Each side chain comprises a glucuronic acid residue between
two mannose units. At most of the terminal mannose units is a pyruvate moiety; the
mannose  nearest  the  main chain carries  a  single  group  at  C-6.  The resulting stiff
polymer chain may exist in solution as a single, double, or triple helix that interacts
with other xanthan gum molecules to form complex, loosely bound networks.
Functional category 
Gelling  agent,  stabilizing  agent,  suspending  agent,  sustained-release  agent,
viscosity-increasing agent.
Application
Department of pharmaceutics               59            JKKMMRF college of pharmacy
Chapter 4                                                                                       Materials & methods
Xanthan gum is used to prepare sustained-release matrix. Xanthan gum has
also been used to produce directly compressed matrices that display a high degree of
swelling  due  to  water  uptake,  and  a  small  amount  of  erosion  due  to  polymer
relaxation.
Safety
The estimated acceptable daily intake for Xanthan gum has been set by the
WHO at up to 10 mg/kg body-weight.
Stability and storage condition 
Aqueous solutions are stable over a wide pH range (pH 3–12), although they
demonstrate maximum stability at pH 4–10 and temperatures of 10–608°C.
Incompatibilities
 Xanthan  gum  is  an  anionic  material  and  is  not  usually  compatible  with
cationic surfactants, polymers, or preservatives, as precipitation occurs.
Handling precautions
Observe normal precautions appropriate to the circumstances and quantity of
material handled. Eye protection and gloves are recommended.
Regulatory status
           GRAS listed. Accepted for use as a food additive in Europe. Included in the
FDA Inactive Ingredients Guide (oral solutions, suspensions, and tablets; rectal and
topical  preparations).  Included  in  nonparenteral  medicines  licensed  in  the  UK.
Included in the Canadian List of Acceptable Non-medicinal Ingredients.
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4.3.3. Excipient profile (Raymond C Rowe, 1995).
 Povidone.
Synonyms 
Kollidon,  Plasdone;  poly  [1-(2-oxo-1-pyrrolidinyl)  ethylene];  polyvidone;
polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer.
Chemical name: 1-Ethenyl-2-pyrrolidinone homopolymer.
Molecular formula: (C6H9NO) n.
Description
Povidone occurs as a fine, white to creamy-white colored, odorless or almost
odourless, hygroscopic powder.
Melting point: Softens at 150 0C.
Solubility
 Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and
water; practically insoluble in ether, hydrocarbons, and mineral oil.
Stability and storage conditions 
Povidone  may  be  stored  under  ordinary  conditions  without  undergoing
decomposition or degradation. However, since the powder is hygroscopic, it should be
stored in an airtight container in a cool, dry place.
Incompatibilities
 It forms molecular adducts in solution with sulfathiazole, sodium salicylate,
salicylic acid, phenobarbital, tannin, and other compounds.
Safety
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When consumed orally,  povidone may be  regarded  as  essentially  nontoxic
since  it  is  not  absorbed  from  the  gastrointestinal  tract  or  mucous  membranes.
Povidone additionally has no irritant effect on the skin and causes no sensitization.
Application 
In  tableting,  povidone  solutions  are  used  as  binders  in  wet  granulation
processes.
Handling precautions
Observe normal precautions appropriate to the circumstances and quantity of
material handled. Eye protection, gloves, and a dust mask are recommended. 
Regulatory status
Accepted for use in Europe as a food additive. Included in the FDA Inactive
Ingredients  Guide  (IM  and  IV  injections,  ophthalmic  preparations,  oral  capsules,
drops,  granules,  suspensions,  and  tablets,  sublingual  tablets,  topical  and  vaginal
preparations). Included in nonparenteral medicines licensed in the UK. Included in the
canadian list of acceptable nonmedicinal ingredients.
 Anhydrous calcium hydrogen phosphate
 Synonyms
Calcium  ortho  phosphate,  Dicalcium  ortho  phosphate,  phosphoric  acid
calcium salt (1: 1).
Chemical Name: Dibasic calcium phosphate.
Description 
Anhydrous dibasic calcium phosphate is a white, odorless, tasteless powder or
crystalline solid.
Empirical formula: CaHPO4
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Solubility: Practically insoluble in ether, ethanol, and water; soluble in dilute acids.
Functional categories: Tablet and capsule diluent.
Angle of repose: 28.3°.
Density (bulk): 0.78 g/cm3.
Density (tapped): 0.82 g/cm3 .
Melting point: Decomposes at 425°C to form calcium pyrophosphate.
Applications
 Anhydrous dibasic calcium phosphate is used both as an excipient and as a
source  of  calcium  in  nutritional  supplements.  It  is  also  used  in  pharmaceutical
products because of its compaction properties, and the good flow properties of the
coarse-grade material.
Incompatibilities 
      Dibasic  calcium  phosphate  should  not  be  used  to  formulate  tetracycline
antibiotics.
Stability and storage conditions 
Dibasic calcium phosphate anhydrous is a nonhygroscopic,  relatively stable
material. Under conditions of high humidity it does not hydrate to form the dihydrate.
The bulk material should be stored in a well-closed container in a dry place.
Safety
Dibasic calcium phosphate anhydrous is widely used in oral pharmaceutical
products,  food products,  and  toothpastes  and  is  generally  regarded  as  a  relatively
nontoxic and nonirritant material.
 Handling precautions
Department of pharmaceutics               63            JKKMMRF college of pharmacy
Chapter 4                                                                                       Materials & methods
Observe normal precautions appropriate to the circumstances and quantity of
material handled. The fine-milled grades can generate nuisance dusts and the use of a
respirator or dust mask may be necessary.
Regulatory status
GRAS listed.  Accepted as a food additive in Europe. Included in the FDA
Inactive  Ingredients  Guide  (oral  capsules  and  tablets).  Included  in  nonparenteral
medicines  licensed  in  Europe.  Included  in  the  Canadian  List  of  Acceptable  Non-
medicinal Ingredients.
Colloidal anhydrous silica
Synonyms
Aerosil,  Cab-O-Sil,  Cab-O-Sil  M-5P,  Colloidal  silica,  Fumed  silica,  light
anhydrous silicic acid, silicic anhydride, silicon dioxide fumed, Wacker HDK.
Chemical name: Silica.
Description
 Colloidal silicon dioxide is submicroscopic fumed silica with a particle size of
about 15 nm. It  is a light, loose, bluish-white-colored, odorless, tasteless, nongritty
amorphous powder.
Structural formula: SiO2.
Solubility
 Practically insoluble in organic solvents, water, and acids, except hydrofluoric
acid; soluble in hot solutions of alkali hydroxide. Forms a colloidal dispersion with
water.
Functional categories 
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Adsorbent,  anticaking agent,  emulsion stabilizer,  glidant,  suspending agent,
tablet disintegrant, thermal stabilizer and viscosity-increasing agent.
pH: 3.5 – 4.4 (4% w/v aqueous dispersion).
Density (bulk): 0.029 – 0.042 g/cm3 .
Applications 
Used as a tablet disintegrant and as an adsorbent dispersing agent for liquids in
powders.
Aerosols                                       -           0.5–2.0 %
Emulsion stabilizer                      -           1.0–5.0 %
Glidant                                         -          0.1–0.5 %
Suspending and thickening agent -         2.0–10.0 %
Incompatibilities
 Incompatible with diethylstilbestrol preparations.
Stability and storage 
It is hygroscopic. Should be stored in a well-closed container. At pH greater
than 7.5 the viscosity-increasing properties of colloidal silicon dioxide are reduced;
and at a pH greater than 10.7 this ability is lost entirely.
Safety
Colloidal  silicon dioxide is  widely used in  oral  and topical  pharmaceutical
products and is generally regarded as an essentially nontoxic and nonirritant excipient.
However,  intraperitoneal  and  subcutaneous  injection  may  produce  local  tissue
reactions  and/or  granulomas.  Colloidal  silicon  dioxide  should  therefore  not  be
administered parenterally.
Handling precautions
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Observe normal precautions appropriate to the circumstances and quantity of
material handled. Eye protection and gloves are recommended. Precautions should be
taken  to  avoid  inhalation  of  colloidal  silicon  dioxide.  In  the  absence  of  suitable
containment facilities, a dust mask should be worn when handling small quantities of
material.  For  larger  quantities,  a  dust  respirator  is  recommended.  Inhalation  of
colloidal silicon dioxide dust may cause irritation to the respiratory tract but it is not
associated with fibrosis of the lungs (silicosis),  which can occur upon exposure to
crystalline silica.
Regulatory acceptance
GRAS listed. Included in the FDA Inactive Ingredients Guide (oral capsules,
suspensions,  and  tablets,  transdermal  and  vaginal  preparations).  Included  in
nonparenteral  medicines  licensed  in  the  UK.  Included  in  the  Canadian  List  of
Acceptable Non-medicinal Ingredients.
Magnesium stearate
Synonyms
Stearic acid magnesium salt, magnesium salt, magnesium octadecanoate.
Chemical name: Octadecanoic acid magnesium salt.
Description 
If  is  a  fine,  white,  precipitated  of  milled,  impalpable  powder  of  low bulk
density, having a faint odor of stearic acid & a characteristic taste.
Structural formula: [CH3(CH2)16COO]2Mg.
Solubility 
It is insoluble in water, ethanol & ether, slightly soluble in warm benzene &
warm ethanol.
Functional categories: Table & capsule lubricant.
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Melting point: 117- 150°C.
Density (bulk): 0.159gm/cm3.
Density (tapped): 0.286gm/cm3.
Stability and storage conditions
 Should be stored in well-closed container  in a cool, dry place.  It  is stable
compound.
Incompatibilities
Incompatible with strong oxidizing agents, strong acids, alkalis & iron salts. It
cannot be used in products containing aspirin, some vitamins, & most alkaloidal salts.
Safety 
It is nontoxic. However, oral consumption of large quantity may result in some
laxative effect or mucosal irritation.
Applications 
Used in cosmetics, food & pharmaceutical formulations and as a lubricant in
capsule & table at concentration between 0.25-5.0%.
Handling precautions
Observe normal precautions appropriate to the circumstances and quantity of
material handled. Eye protection and gloves are recommended. Excessive inhalation
of magnesium stearate dust may cause upper respiratory tract discomfort, coughing,
and choking. Magnesium stearate should be handled in a well ventilated environment;
a respirator is recommended.
Regulatory acceptance
GRAS listed. Accepted as a food additive in the UK. Included in the FDA
Inactive Ingredients Guide (oral capsules, powders, and tablets, buccal and vaginal
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tablets, topical preparations). Included in nonparenteral medicines licensed in the UK.
Included in the Canadian list of acceptable non-medicinal ingredients.
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4.4. Preformulation studies
Before formulation of drug substances into a dosage form, it is essential that
calibration graph,drug & polymer should be chemically and physically characterized.
Preformulation studies gives the information needed to define the nature of the drug
substance and provide a framework for  the drug combination with pharmaceutical
excipients in the fabrication of a dosage form.
Construction of calibration curve
An accurately weighed 100 mg of  Trimetazidine  was dissolved in phosphate
buffer of pH 6.8 separately and make up the volume up to 100 ml in a volumetric
flask (Stock Solution: I, 1000 µg/ml) . From this 10 ml of solution were pipette out
and make up the volume up to 100 ml (Stock Solution: II,  100 µg/ml).  Then the
aliquots  were  prepared,  whose concentration ranging from 0 to  33 µg/ml  and the
absorbance  was  measured  at  231  nm  (Abhijit.  N  et  al.,  2010)  by  using  UV
Spectrophotometer (Shimadzu, Model No: 2450) against the blank. 
Drug-excipient compatibility studies by FT-IR
One of the requirements for the selection of suitable excipients or carriers for
pharmaceutical formulation is its compatibility. Therefore in the present work a study
was carried out by using infrared spectrophotometer to find out if there is any possible
chemical interaction of  Trimetazidine dihydrochloride drug with Polyethylene oxide
WSR 301NF, HPMC K200M,  Xanthan gum and placebo used for the study.
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Procedure
Weighed amount of drug (1 mg) was mixed with 99 mg of potassium bromide
(dried at 40-50oC). The mixture was taken and compressed under 7-ton pressure in a
hydraulic  press  to  form  a  transparent  pellet.  The  pellet  was  scanned  in  IR
spectrophotometer.
Drug excipient compatibility studies by force degradation studies
The Binary mixtures of drug and excipients (1:1) were prepared, and packed
in  both  closed  vials  and  kept  in  both  long  term  and  accelerated  environmental
conditions (250C/60% RH and 400C/75% RH) for 1 month. At the end of 1 month
period all the samples were observed physically.
4.5. Preparation of a sustained release tablets
Design of formula and composition
The  design  of  tablets  involved  various  compromises  on  the  part  of  the
formulator, to produce desired product properties. It involves the correct selection and
balance of excipients materials for active ingredients to achieve the desired response.
Based on primary information collected from market  samples and previous
experience  with  the  manufacturing  of  various  products,  the  following  tentative
product specifications were proposed before starting the formulation trials.
Type of sustained release system proposed
Matrix with SR controlling tablets. 
Justification for the design of the formula composition
In  addition  to  the  active,  Trimetazidine  dihydrochloride 60  mg SR  tablets
contained a number of inert materials as diluents, binders, and lubricants, compression
and release characteristics to the formulation. The justification for the inclusion of
these functional additives is briefly described below.
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Diluents
They are inert materials added to increase the bulk in order to make the tablet
with a desired particle size for compression.
 Dicalcium  phosphate  anhydrous  was  used  in  the  present  development  as
directly compressible materials and improves the flow properties of the blend. 
Binders
Materials  used  to  impart  cohesive  quality  to  the  powdered  materials  are
referred  to  as  binders.  They impart  cohesiveness  to  the  tablet  formulation  which
insures the tablet remaining intact after compression as well as improving the free
flowing qualities by the formulation of granules of desired hardness and size. In the
present study povidone K90F was selected as binder.
 
Lubricants
They prevent the adhesion of the tablet material to the surface of the dies and
punches reduces inter-particle friction, facilitate the ejection of the tablet from the die
cavity and improve the rate of flow of the tablet granulation.
 
 In  the  present  study,  Magnesium  stearate  was  used  as  lubricant.  It  is
hydrophobic in nature. It was a proper choice as the tablet did not show any tendency
to stick  to  the  side of  the die.  The tablets  were  found to  be  satisfactory and  the
dissolution profile of the drug substance was satisfactory with the use of Magnesium
stearate.
Dispensing of materials
All the  solid  raw materials are dispensed, packed in  individual  cleaned Poly
ethylene bags and labeled.
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4.6. Formulation
Table 3: Composition of SR tablets of Trimetazidine dihydrochloride.
S.
N
o
Ingredients
F1
(mg
)
F2
(mg
)
F3
(mg
)
F4
(mg
)
F5
(mg
)
F6
(mg
)
F7
(mg
)
F8
(mg
)
1 Trimetazidine diHcl 60 60 60 60 60 60 60 60
2 Dicalcium phosphate 235 175 115 55 235 175 115 55
3 Povidone K90F 10 10 10 10 10 10 10 10
4 Xanthan gum 120 120 120 120 120 120 120 120
5 HPMC K200M __ ---- ---- ---- 60 120 180 240
6 Polyox WSR 303 60 120 180 240 __ ---- ---- ---
7 Colloidal
anhydroussilica 10 10 10 10 10 10 10 10
8 Magnesium stearate 5 5 5 5 5 5 5 5
9 One tablet weight 500 500 500 500 500 500 500 500
Sifting
Separately  sift  Trimetazidine  dihydrochloride,  Colloidal  anhydrous  silica,
Polyethylene oxide [Sentry    Polyox WSR 303 LEO], Povidone K90 , Hydroxypropyl
methyl cellulose K 200M, Xanthan gum and anhydrous calcium hydrogen phosphate
through #30 mesh and  Magnesium stearate through #60 mesh. Collect all the above
sifted materials individually into a double lined polyethylene bag.
Department of pharmaceutics              72             JKKMMRF college of pharmacy
Chapter 4                                                                                       Materials & methods
Mixing
Load  sifted  Trimetazidine  dihydrochloride, anhydrous  calcium  hydrogen
phosphate, Colloidal anhydrous silica and Povidone K 90 into octagonal blender and
mix for 10 minutes.
Pre-Lubrication and Lubrication
To the above blend, add Xanthan gum/ polyox / HPMC and pre-lubricate for
10 minutes.  Lubricate  the  above blend  with Magnesium stearate  in  the  octagonal
blender for 5 minutes.
4.7. Evaluation of Blend
Angle of repose: 
In order to determine the flow property, the Angle of repose was determined. It
is the maximum angle that can be obtained between the free standing surface of the
powder heap and the horizontal plane.
θ = tan -1 (h/r)
          Where,
h = height
r = radius
θ = angle of repose
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Procedure
An accurately weighed sample was taken. A funnel was fixed in the stand in
such a way that the tip of the funnel was at the height of 6 cm from the surface. The
sample was passed through the funnel slowly to form a heap.  The height and the
circumference of the powder heap formed were measured. The radius was measured
and the angle of repose was determined using the above formula. This was repeated
three times for a sample.
Determination of bulk density and tapped density
A quantity of 10 gm of the powder (W) from each formula was introduced into
a 50 ml measuring cylinder. After the initial volume was observed, the cylinder was
allowed to fall under its own weight onto a hard surface from the height of 2.5 cm at 2
sec intervals. The tapping was continued until no further change in volume was noted
(Shah D et al., 1997, Aulton ME, 1988).
The bulk density and tapped density were calculated using the following formulas
Bulk density = W / VO
Tapped density = W / Vf
Where, 
W = weight of the powder.
VO = initial volume.
Vf = final volume.
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Hausner’s Ratio
 It indicates the flow properties of the powder and is measured by the ratio of
tapped density to the bulk density (Rajiv Garg, 2002).
Hausner’s Ratio = Tapped density/Bulk density
Table 4: Limits of hausner’s ratio as per USP
S. No Hausner’s ratio Property
1. Less than 1.25 Free flow
2. 1.25 to 1.5 Glidant to be added
3. More than 1.5 Poor flow
Compressibility index (Carr’s indices)
Compressibility index is an important measure that can be obtained from the
bulk and tapped densities. In theory, less the compressibility of a material, it is more
flowable.  A material  having values  of  less  than 20 to  30% is  defined as  the  free
flowing material (Aulton ME, 1988).
CI = 100 (VO – Vf)/V0
Table 5: Flow characteristics specifications
% Comp. Index Properties
5-12 Free flowing
12-16 Good
18-21 Fair
23-35 Poor
33-38 Very poor
>40 Extremely poor
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Compression
Compress the lubricated blend using punches mentioned in Table 6 and the
tablet parameters are given in Table 7.
Table 6: Punches specification
Punch dimension 10.50 mm
Punch shape Circular, Standard concave punches
Upper punch Plain
Lower punch Plain
Table 7: Tablet parameters as follows
Parameters Specification
Description Circular, biconcave, uncoated tablets, plain on both
sides
Theoretical mass of
tablet 500.00 mg
Average mass 500.00 mg ± 3.0 %
Uniformity of mass NMT 2/20 ± 7.5% and none by ± 15.0 % mass.
Diameter 10.50 ± 0.20 mm
Thickness 5.30± 0.30 mm
Hardness 7-15KP/70-150 N
Friability NMT 1.0 %m/m.
4.8. Evaluation of SR tablets 
General appearance
The  general  appearance  of  a  tablet,  its  identity  and  general  elegance  is
essential for consumer acceptance, for control of lot-to-lot uniformity and tablet-to-
tablet  uniformity.  The control  of  general  appearance involves  the measurement  of
size, shape, color, presence or absence of odor, taste etc.
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Size & shape
It can be dimensionally described & controlled. The thickness of a tablet is
only  variables.  Tablet  thickness  can  be  measured  by  Vernier  caliper  or  by  other
device. Tablet thickness should be controlled within a ± 7.5% variation of standard
value. 
Hardness
Tablet  requires  a  certain  amount  of  strength  or  hardness  and  resistance  to
friability to withstand mechanical shakes of handling in manufacture, packaging and
shipping. Hardness generally measures the tablet crushing strength (Khemariya. P et
al., 2010).
Friability
Friability of a tablet can determine in laboratory by Roche friabilator.  This
consist of a plastic chamber that revolves at 25 rpm, nearer to 6.5 grams of tablets are
dropping through a distance of Six inches in the friabilator, which is then operate for
100 revolutions. The tablets are reweighed. Compress tablet that lose less than 0.1 to
0.5 % of the Tablet weigh are consider acceptable.
The percentage friability was measured by using the following formula
% F = {1-(W / Wo)} x 100
           Where,              
%F = friability in percentage
Wo = Initial weight of tablet
W = Weight of tablets after revolution.
Weight variation test
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Take  20  tablets  and  weighed  individually.  Calculate  average  weight  and
compare the individual tablet weight to the average. The tablet pass the U.S.P. test if
not more that 2 tablets are outside the percentage limit and if no tablet differs by more
than 2 times the percentage limit (Pharmacopoeia of India, 1996).
Table 8: Limits of weight variation as per USP
Average weight of tablet (X mg) Maximum % difference allowed
130 mg or less 10
130 mg to 324 mg 7.5
More than 324 mg 5
% Maximum positive deviation = (WH –A/ A) X 100
% Minimum negative deviation = (WL - A / A) X 100
                           Where,
WH = Highest weight in mg.
WL = Lowest weight in mg.
A = Average weight of tablet in mg.
Drug content uniformity (Assay)
 The formulated  Trimetazidine  dihydrochloride SR tablets  were  assayed  for
drug content.
Method 
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From each batch of prepared tablets, ten tablets were collected randomly and
powdered. A quantity of powder equivalent to weight of one tablet was transferred in
to a 100 ml volumetric flask, to this 20 ml of methanol was added and then dissolve
the substance and then sonicate for 15 min to get a clear solution, then make up to 100
ml with Phosphate Buffer pH 6.8 and then filter the solution through 0.45 µm filter
and suitable dilutions were prepared with pH 6.8. Same concentration of the standard
solution  was  also  prepared.  The  drug  content  was  estimated  by  recording  the
absorbance at 231 nm by using UV-Visible spectrophotometer. 
Calculation
Calculate the estimation of  Trimetazidine dihydrochloride per tablet by using
the formula:
Test absorbanceX Standard weight (mg) X Standard dilutions X900 X Standard purity
Standard absorbance   X    100     X   Test dilutions X      Lable claim
Dissolution (By UV Method)
Instrument     :  UV-spectrophotometer
Wave length    :   231 nm
Dissolution parameters
Medium : Phosphate Buffer pH 6.8
Volume : 900 ml
Apparatus : USP Type-II (Paddle), with Sinkers.
RPM : 50
Time intervals : 1, 2, 4, 8, 12, 18, 21 and 24
Temperature  : 37.0 ± 0.5°C
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Sample preparation
Transfer  one  tablet  into  each  dissolution  bowels  and  run  the  dissolution
apparatus as per dissolution parameters. Withdraw 10 ml of sample solution through
auto  sampler  containing  free  flow  filter,  at  the  sampling  time.  Replace  aliquots
withdrawn  for  analysis  with  equal  volumes  of  dissolution  medium  which  is
maintained at 37 ± 0.5°C.
Standard solution
Dissolve an accurately weighed quantity of Trimetazidine dihydrochloride 100
mg in 100 ml of Phosphate Buffer pH 6.8 (standard stock solution) separately, from
this 10 ml of solution were pipette out and make up to 100 ml with Phosphate buffer
pH 6.8 and the aliquot of concentration of 33 µg/ml was prepared and measured the
absorbance  at  231  nm by using UV visible  spectrophotometer  (Raj  kumar  et  al.,
2010).
Dissolution Medium
900 ml of Phosphate Buffer pH 6.8 (wipo patent application, 2009).
Buffer Preparation
Phosphate buffer pH 6.8
6.8  gm  of  Potassium  dihydrogen  ortho  phosphate  and  0.8  gm  of  sodium
hydroxide pellets  are added to 1000 ml of  distilled water  and adjust  the pH with
sodium hydroxide pellets.
Calculation 
Calculate the % release of  Trimetazidine dihydrochloride per tablet by using
the formula:
Test absorbance X Standard weight (mg) X Sample dilutions X 900 X Standard purity
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Standard absorbance X        100            X   Test dilutions      X   Label claim
Table 9: Limits of In Vitro dissolution studies
Time
(hrs)
Amount
dissolved
2 NLT 25%
4 35-40%
8 50-60 %
12 60-70 %
18 80-90%
21 NLT 90%
The results of in vitro release profiles obtained for all the formulations were fitted into
three models of data treatment as follows 
1. Cumulative percent drug released versus time (zero-order kinetic model). 
2. Cumulative percent drug released versus square root of time (Higuchi’s model). 
3.  Log  cumulative  percent  drug  released  versus  log  time  (Korsmeyer-Peppas
equation). 
1. Zero order kinetics 
A zero-order release would be predicted by the following equation. 
At = A0 – K0t …1
Where,
At = Drug release at time‘t’
A0 = Initial drug concentration
K0 = Zero-order rate constant (hr
-1).
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When the data is plotted as cumulative percent drug release versus time, if the
plot is linear then the data obeys zero-order release kinetics, with a slope equal to K0. 
2. Higuchi’s Model
Drug released from the matrix  devices  by diffusion has  been described by
following Higuchi’s classical diffusion equation. 
Q = [Dε/τ(2A- εCs) CS t] ½ …2
Where,
Q = Amount of drug released at time‘t’
D = Diffusion coefficient of the drug in the matrix
A = Total amount of drug in unit volume of matrix
CS = The solubility of the drug in the diffusion medium
ε = Porosity of the matrix
τ = Tortuosity
t = Time (hrs) at which ‘Q’ amount of drug is released.
Equation-2 may be simplified if one assumes that D, CS  and A are constant. Then
equation-2 becomes:  
Q = Kt½ …3
When the data is plotted according to equation-3 i.e., cumulative drug released versus
square root of time, yields a straight line, indicating that the drug was released by
diffusion mechanism. The slope is equal to ‘K’.
 
3. Korsmeyer and Peppas model
The release rates from sustained release polymeric matrices can be described
by the equation (4) proposed by Korsmeyer et al. 
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Q=K1tn......... (4)
Q  is  the  percentage  of  drug  released  at  time‘t’,  K  is  a  kinetic  constant
incorporating  structural  and  geometric  characteristics  of  the  tablets  and  ‘n’ is  the
diffusional exponent indicative of the release mechanism. 
For Fickian release,  n=0.45 while for anomalous (Non-fickian) transport,  n
ranges between 0.45 and 0.89 and for zero order release, n = 0.89 (Peppas, 1985).
In- vitro drug release studies for marketed product
The in vitro drug release studies were performed for marketed product using
dissolution medium as 6.8 pH Phosphate buffer volume 900 ml at 50 rpm, USP II
apparatus. By using UV-spectrophotometer at 231 nm.
4.9. Stability studies
The purpose of stability testing is to provide evidence on how the quality of a
drug substance or drug product varies with time under the influence of a variety of
environmental  factors  such  as  temperature,  humidity  and  light,  enabling
recommended storage conditions, re-test periods and shelf-lives.
The  International  Conference  on  Harmonization  (ICH)  guidelines  titled
“Stability Testing of New Drug substance and Products” (QIA) describes the stability
test  requirements  for  drug  registration  for  drug  registration  applications  in  the
European Union, Japan and The United States of America.
ICH specifies the length of study and storage conditions
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Table 10: Stability storage conditions
Study Storage condition Time period
Long term 25ºC ± 2 ºC/ 60% RH ± 5% RH 12 months
Intermediate 30ºC ± 2 ºC/ 65% RH ± 5%RH 6 months
Accelerated 40ºC ± 2 ºC/ 75% RH ± 5% RH 6 months
Stability studies were conducted according to ICH Guidelines; the optimized
formulation was packed in Alu-Alu blisters and stored at three different conditions i.e.
Long term, intermediate and accelerated conditions in a stability chamber for a period
of 3months. The samples were evaluated for assay and dissolution studies at regular
intervals.
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5. RESULTS AND DISCUSSION
Trimetazidine dihydrochloride is a metabolic agent, acts at the cellular level to 
improve myocardial metabolism at the time of ischemia. In case angina pectoris 
Trimetazidine dihydrochloride increases coronary flow reserve, thereby delaying the 
onset of ischemia associated with exercise, limits rapid swings in blood 
pressure without any significant variations in heart rate, significantly decreases the 
frequency of angina attacks, and leads to a significant decrease in the use of nitrates. 
It improves left ventricular function in diabetic patients with coronary heart disease. 
Recently, it has been shown to be effective in patients with heart failure of different 
etiologies. Multiple dose administration at intervals of 6 to 8 hours is difficult for a 
patient with angina or a hypertensive patient. This can lead to patient non compliance.
 Trimetazidine dihydrochloride with all evident advantages proved to be a 
suitable candidate for development of a sustained release dosage form. In the present 
study, HPMC K200M, Poly ethylene oxide WSR 301 and xanthan gum which are 
commonly used in hydrophilic matrix drug delivery systems, have been employed to 
formulate sustained release tablets of Trimetazidine dihydrochloride.
5.1. Preformulation Studies
Calibration graph
The Calibration Graph of Trimetazidine dihydrochloride performed in 
phosphate buffer pH 6.8. It shows regression value 0.999 so it passes linearity.
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Table 11: Calibration curve data of Trimetazidine dihydrochloride.
Concentration(µg/ml) Absorbance at 231nm
0 0
5.5 0.133
11 0.256
16.5 0.380
22 0.494
27.5 0.629
33 0.732
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Figure 7: Calibration curve of Trimetazidne Dihydrochloride (pH 6.8)
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5.2. Drug –polymer compatibility studies by FTIR
Figure 8: FTIR Spectra of Trimetazidine Dihydrochloride.
Figure 9:  FTIR spectra of HPMC K200M.
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Figure 10: FTIR Spectra of Poly Ethylene Oxide WSR 301.
Figure 11: FTIR Spectra of Xanthan gum.
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Figure 12:  FTIR Spectra of Trimetazidine dihydrochloride and HPMC K200M.
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Figure 13: FTIR Spectra of Trimetazidine dihydrochloride & Polyox WSR
301.
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Figure 14: FTIR Spectra of Trimetazidine dihydrochloride and Xanthan gum.
Figure 15: FTIR Spectra of Trimetazidine dihydrochloride and Placebo.
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The FTIR spectra of Trimetazidine dihydrochloride, HPMC K200M, Poly 
ethylene oxide WSR 301 and Xanthan gum and the combination of drug and 
polymers were shown no significant interaction between drug and polymer. The FTIR
spectra’s of Trimetazidine dihydrochloride, HPMC K200M, Poly ethylene oxide WSR
301, Xanthan gum of drug along with polymers are shown in figures 8 to 15.
Trimetazidine dihydrochloride functional group characterstic peaks are 
observed in drug and with combination of polymers as shown in table 12 so it 
indicates there was no interaction between drug and other excipients.
Table 12: FTIR interpretation results for drug and polymers
S.
No Composition
Functional group (  v   in cm-3)
N-H(BN) C-N(ST) C=C(ST) C-O(ST)
1 Characterstick peak 1650-1580 1340-1020 1600-1500 1260-1000
2 Trimetazidine dihydrochloride 1625 1285 1590 1100
3 API+HPMC k 200m 1610 1285 1589 1100
4 API+ Polyox WSR303 1612 1288.49 1595 1102
5 API+Xanthan gum 1601.93 1288.49 1505 1102
6 API+Placebo 1605 1288.49 1505 1102
5.3. Drug Excipient Compatibility studies by force degradation studies: 
Compatibility studies at different temperature and relative humidity showed 
that drug itself was stable at higher temperature and relative humidity as well as 
compatible with all above used excipients. 
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Table 13: Drug excipient compatibility studies by forced degradation
Drug + Excipient Initial
First month Observation
Comp
atible
25ºC/60%RH 40ºC/75% RH
Drug White Powder No change No change Yes
Drug + HPMC CreamyWhite No change No change Yes
Drug + Polyox White Powder No change No change Yes
Drug + Xanthan gum White Powder No change No change Yes
Drug + DCP White Powder No change No change Yes
Drug + Povidone White Powder No change No change Yes
Drug + Silica White Powder No change No change Yes
Drug + Magnesiumstearate White Powder No change No change Yes
5.4. Evaluation Studies
Blend evaluation parameters
The flow properties and other derived properties evaluated for all 6 
formulations were proved to be within limits showing good flow properties. The 
physical properties like bulk density, tapped density, angle of repose, compressibility 
index and Hausner’s ratio were calculated and tabulated in table 14.
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Table 14: Physico chemical parameters of blend
S
No
Formulation
s
BD(gm/ml) TD(gm/ml) AR CI HR
1 F1 0.415 0458 24.51 12.5 1.09
2 F2 0.425 0.476 24.84 12.0 1.12
3 F3 0.416 0.476 27.96 14.4 1.14
4 F4 0.408 0.470 30.25 15.1 1.15
5 F5 0.402 0.465 30.01 14.9 1.14
6 F6 0.384 0.434 25.58 13.0 1.13
7 F7 0.370 0.430 28.17 16.2 1.16
8 F8 0.374 0.442 32.46 18.2 1.18
All values were average of 3
Physicochemical properties of tablets
The prepared Trimetazidine sustained release tablets were characterized based 
upon their physicochemical characteristics like thickness, weight variation, hardness, 
friability and drug content.
 Weight variation
 The weight variation of the tablet was found to be in the range of 497.5 mg to 
504.6 mg. The Results were tabulated in table 16. 
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Thickness 
The tablet thickness were observed by using digital vernier caliper and found 
to be in the range of 5.20 mm to 5.28 mm the results were observed in table 15.
 Hardness
The difference in the hardness was affect the release of the drug from 
hydrophilic matrices which is 8.1 to 11.02 KP released by diffusion through the gel 
layer and/or erosion of this layer and is independent of the dry state of the tablet. The 
values were given in table 15.
Friability
Tablet strength was tested by Roche Friabilator. The friability of all 
formulations were observed within the range of 0.24% to 0.33%. The values were 
given in table 15.
Drug content
The Drug content of all formulations were observed within the range of 
98.48% - 99.47% The values were given in table 15.
Table 15: Physicochemical parameters of Trimetazidine dihydrochloride ER tablet
formulations.
Formulatio
n
Thicknes
s
(mm)
Hardnes
s
(Kp)
Friabilit
y
(%w/w)
Assay
(%)
Meanweigh
t
(mg)
Standar
d
deviatio
n
F1 5.19 8.18 0.36 98.53 500.8 2.19
F2 5.20 8.10 0.33 98.48 500.67 2.21
F3 5.29 8.36 0.25 99.03 500.66 2.19
F4 5.22 8.96 0.26 98.66 500.05 2.14
F5 5.21 8.81 0.24 99.41 500.4 2.16
F6 5.25 9.16 0.25 99.47 500.8 2.18
F7 5.22 10.68 0.24 99.73 500.56 2.41
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F8 5.28 11.02 0.25 98.49 500.45 1.99
In-vitro drug release studies.
Table 16: In-Vitro Dissolution profile for Trimetazidine Dihydrochloride ER
tablets of F1 to F8
Time
 (Hrs) F1 F2 F3 F4 F5 F6 F7 F8
1 23.645 21.07 20.22 19.39 20.82 19.08 16.45 14.08
2 40.25 39.71 37.32 35.62 35.41 33.53 26.59 24.46
4 60.43 57.89 53.46 48.26 48.15 44.91 37.52 34.91
8 82.15 80.23 72.69 69.45 61.58 60.56 51.75 48.49
12 88.65 85.25 90.31 87.09 80.15 79.31 64.86 63.03
18 95.31 92.69 92.82 91.99 83.54 82.54 83.59 79.98
21 98.85 95.78 95.20 92.13 88.25 87.29 91.68 87.12
24 99.25 96.12 95.72 95.56 89.99 90.64 99.89 93.18
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Figure 16: Invitro dissolution profile for Trimetazidine Dihydrochloride ER
tablets for formulations: F1 to F8
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Formulation of Trimetazidine dihydrochloride was prepared with polymers 
HPMC K200M, Ploy ethylene Oxide WSR 301 and Xanthan gum individually 
concentration of (2x and 3x) by direct compression technique. In vitro dissolution 
profile of HPMC K200M, Poly ethylene Oxide WSR 301 concentrations of (2x and 
3x) the drug release was nearer to 97% at end of 8-12 hours, Xanthan gum showed the
drug release was near to 95% 12-15 hrs.
Then formulations of Trimetazidine dihydrochloride were prepared with Poly 
ethylene oxide WSR 301: Xanthan gum and HPMC K200M: Xanthan gum 
combinations with different concentrations by direct compression technique. The 
formulation of F7 and 8 showed comparatively high hardness value of 10KP. This 
could be a presence of more concentration of HPMC K200M which is responsible for 
more hardness of the tablet. The low hardness value observed with formulation F1 
and 2 due to the presence of less concentration of poly ethylene oxide WSR 301, 
which is generally decreases the hardness of tablet. Tablet hardness is not an absolute 
indicator of strength. Another measure of tablet strength is friability. All formulations 
showed less than 1% w/w friability that indicates the ability of tablets to withstand 
shocks which may encountered during transport. All the tablet formulations showed 
acceptable pharmacotechnical properties and compiled with In house specification for
weight variation, assay, hardness and friability.
The in vitro drug release characteristics were studied in simulated gastric and 
intestinal fluid for a period of 24 hours using USP II dissolution apparatus. Initially 
tablets were prepared with a drug-polymer ratio of 1:1. But the tablets released 100% 
of Trimetazidine dihydrochloride within 3 hours. In an attempt to prolong the release 
of the drug, the concentration of polymer was increased. The tablets were prepared 
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with the ratio of 1:2 and 1:3. The drug release also 100% within 12 hours. Based on 
the results of in vitro dissolution, the tablets were prepared in combination of 
polymers.
The drug was mixed with different proportions of Xanthan gum and Poly 
Ethylene Oxide WSR 301 and HPMC K200M. The 2x concentration of Xanthan gum 
was mixed with 1x, 2x, 3x and 4x concentration of Poly Ethylene oxide WSR 301. 
When the concentration of poly ethylene oxide increases it retards the drug release. 
The formulations were prepared with same concentration of Xanthan gum and low 
concentration of Poly ethylene oxide WSR 301 only retards the drug release. Firstly, 
the formulation F 1 was prepared with 2x:2x concentration of Xanthan gum and Poly 
ethylene oxide WSR 301, the tablets shown 85% of drug release with in 12hours. This
is due to the less concentration of Poly ethylene oxide WSR 301. Secondly, F 2 was 
prepared with 2x:3x concentration of Xanthan gum and Poly ethylene oxide WSR 
301, it shows drug release 92% within 18 hours. Third formulation was prepared with 
2x:3x concentration of Xanthan gum and Poly ethylene oxide WSR 301, also shows 
like second these tablets showed 98% of drug release within 18 hours due to the high 
concentration of poly ethylene oxide. Next further 3 batches are prepared with same 
concentration of Xanthan gum and 2x, 3x and 4x concentration of HPMC K200M. 
The formulation F5 was showed that it releases the 87% of Trimetazidine 
dihydrochloride within 21 hours. Fifth formulation F7 was prepared with 2x:4x 
concentration of Xanthan gum and HPMC K200M , it shows  the  drug release 99% 
within 24 hrs and the blend of these formulation was  showed good compressibility 
and flow properties. The formulation F 8 showed 93% of drug release at the end of 24
hours, this is due to the increased concentration of HPMC K200M and increased 
hardness of tablets.
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The F1 to F3 showed slow release of Trimetazidine dihydrochloride in the 
initial hours then continuous shows barest release, which is probably due to faster 
dissolution of highly water soluble drug from core and its diffusion out of matrix 
forming the pores for the entry of solvent molecules. Among all these formulation, the
F3  showing 25-30% of drug release within 2 hours and 99% of drug release at the 
end of 24 hours. This formulation can be considered as a successful formulation since 
they showed little deviation from the theoretical release pattern throughout the 
dissolution period.
Table 17: In-Vitro drug release for marketed product
S.
NO Time (hrs)
Marketed product
(%)
1 1 20.12
2 2 23.84
3 4 42.74
4 8 52.51
5 12 69.19
6 18 80.16
7 21 93.51
8 24 96.07
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Figure 17: Comparison of in vitro drug release profile for marketed0 product &
Optimized formulation F7
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In-vitro release kinetics
Data of in vitro drug release were fit into different equations and kinetic 
models to explain the release kinetics of Trimetazidine from the sustained release 
tablet. The kinetic models used were a Zero-order equation, Higuchi’s model and 
Peppa’s models. The obtained results in these formulations were plotted in various 
model treatment are as follows. I.e. Cumulative percentage drug release Vs Square 
root of time (Higuchi’s) and Log cumulative percentage release Vs Log time 
(Peppa's). To know the mechanism of drug release from sustained release tablet, the 
drug release data was fit into Higuchi’s models. 
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Mechanism of drug release
To find out the mechanism of drug release from hydrophilic matrices, the in 
vitro dissolution data of each formulation with different kinetic drug release 
equations. Namely Zero order: Q=K0t; Higuchi’s square rate at time: Q=KHt1/2 and 
Peppa’s: F=Kmtn, where Q is amount of drug release at time t, F is Fraction of drug 
release at time t, K0 is zero order kinetic drug release constant, KH is Higuchi’s square 
root of time kinetic drug release constant, Km is constant incorporating geometric and 
structural characteristic of tablet and n is the diffusion exponent indicative of the 
release mechanism. The correlation coefficient values (R) indicate the kinetic of drug 
release was zero order and the mechanism of drug release by Peppa’s model indicates 
the non fickian evidenced with diffusion.
Table 18: In-Vitro drug release kinetics for optimized formulation: F7
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Zero order data Higuchi’s data Peppa’s data
Time (hrs) Cumulaive.% release √T
Cumulative
. % release log time
log
cumulative
. % release
0 0 0 0
1 16.45 1.00 16.45 0 1.2
2 26.59 1.41 26.59 0.34 1.42
4 37.52 2.00 37.52 0.60 1.57
8 51.75 2.83 51.75 0.90 1.71
12 64.86 3.45 64.86 1.07 1.81
18 83.59 4.24 83.59 1.25 1.92
21 91.68 4.58 91.68 1.32 1.96
24 99.89 4.90 99.89 1.38 1.99
Chapter 5                                                                                      Results & Discussion
Figure 18: Zero order plot  for optimized formulation F7
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Figure 19: Higuchi's plot for optimized formulation: F7
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Figure 20: Peppa's plot for optimized formulation F7
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5.5. Stability studies
 The stability studies were carried out according to ICH guidelines for 
optimized formulation i.e. F7. The stability studies were carried out under 3 
conditions i.e. Long term stability (25±20C/60% ±5% RH),Intermediate(30±20C/65% 
±5%)and Accelerated stability studies (40±20C/75% ±5% RH). The tablets were 
packed in Alu-Alu blister packing. Then tablets were stored under 3 conditions and 
the tablets were withdrawn at every one month and evaluate the tablet parameters like 
description, assay and dissolution. 
Sample were collected at an interval of 1,2 and 3rd  months and evaluated. 
Discription, Assay and dissolution profile of F7 stored at three conditions in 1M, 2M 
and 3M samples  was found to be similar with that of  initial samples.
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Table 19: Physical evaluation of stability studies for optimized formulation (F7)
At 3 different conditions carried out for 3 months duration.
Mont
h
Cummulative % drug release (time in Hrs)
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Test
1 2 4 8 12 18 21 24
Long 
-term
1 16.57 26.68 37.12 52.9 63.33 82.86 91.76 99.23
2 16.7 26.87 37.0 52.62 64.08 82.61 92.15 99.13
3 15.52 26.41 37.55 53.31 63.54 81.26 91.48 99.19
Inter-
mediate
1 15.45 26.75 36.95 53.47 64.09 83.19 91.55 99.33
2 16.82 27.02 36.25 52.89 64.34 82.33 91.97 99.67
3 16.72 27.35 37.07 53.02 64.48 83.39 91.62 99.08
Accel-
erated
1 15.48 26.92 37.08 52.74 63.43 82.32 92.31 99.48
2 16.91 25.99 35.63 54.24 64.24 82.94 91.12 99.81
3 15.7 25.98 34.77 51.70 62.08 81.18 90.16 99.15
Table 20: Cummulative percentage release of stability studies of optimized
formulation (F7) at 3 different conditions carried out for 3 months duration.
Figure 21:In Vitro Dissolution study for optimized formulation 
(F7)  at 3 different conditions (after 3 month).
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6. SUMMARY & CONCLUSION
 The present study was carried out to develop  Trimetazidine dihydrochloride
modified release matrix tablets in combination of three hydrophilic polymers
for safe and effective action. Matrix tablets with   HPMC K 200, Xanthan
gum, Povidone  were prepared by direct compression method and evaluated.
Matrix is also done in order to achieve the release of drug as per expectation.
 The FT-IR spectroscopy study was carried out to know the preformulation and
Compatibility of the excipients with Trimetazidine dihydrochloride, the active
constituent of the formulation. Results were found no significance changes in
characteristic peaks of drug in the recorded IR spectrum. These preformulation
and compatibility study were confirmed the drug and other excipients in the
formulation are compatible with each other.   
 The Matrix tablets were prepared by Direct Compression Method. The angle
of  repose  of  the  powder  mixture  was  found  to  have  25  to  32.  The  flow
property of the powder was excellent that was confirmed by the determination
of  angle  of  repose  which  indicates  better  uniformity  of  weight.
Compressibility index (%) of formulations was observed between 12.782% to
18.252% that showed excellent compresibility.
 The  matrix  tablets  were  compressed  by  applying  maximum  force  of
compression and the hardness of tablets was found to be in the range of 8 Kp
to 11 Kp. Appreciable hardness of the matrix tablets indicated retardation in
the release as observed in dissolution profile.
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 The release of F1 and F2 were not sustained the release of the drug and results
were  found  upto  drug  released  82.13%  and  81.47%  within  8  hours
respectively.  Formulations F3 and F4 showed the drug release 92.41% and
91.93%  in  18  hours  respectively,  which  indicates  that  by  increasing  the
concentration of  polyox the drug release was sustained. The release rates was
sustained in formulations F1 to F4 but drug release pattern was not  close
to theoretical release profile.  
 The formulation F5 (drug & polymer 1:1) showed the drug release 80.93% for
12 hours, in order to minimize the retardation of drug release ratio of HPMC
was increased to twice and the drug release was 79%, in formulation F6. Then
in order to achieve better release drug by change the proportional (ratio) of
both polymers. The formulation F7 has showed 99.89% drug released for 24
hrs on increasing the concentration of polymer in the ratio of 1:3.
 Satisfactory descriptions of kinetic model of the formulations were found good
according to higuchi’s kinetic model. The ideal properties of matrix tablets are
sufficient  release  of  drug  in  pH  6.8  phosphate  buffer  solution,  so  it  was
necessary to select an appropriate drug release between HPMC and Polyox.
The formulation F7 found to be best.
 The comparative study were performed between my optimized formulation F7
Vs Marketed product (Cardimax),  were found to be better control of drug
release F7 showed 99.89%  and marketed product showed 96.07% at 24 hours
In-Vitro release studies.
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 Stability studies were carried out for optimized formulation F7 were showed
no significance changes in physical  parameters.  Stability studies are carried
out  for  3  months  at  three  different  conditions  (Long  term,  intermediate,
accelerated)  in  various  storage  conditions.  Also  there  was  no  remarkable
change in the content of matrix tablets. 
 Hence it can be concluded that once daily extended release matrix tablet of
Trimetazidine  dihydrochloride having  satisfactory  extended  release  profile
which  may  provide  an  increased  therapeutic  efficacy.  The  developed
formulation overcome and alleviates the drawback and limitation of extended
release preparations.
+
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